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I.  General Information 
 
Unless otherwise noted, reagents received from commercial suppliers were used as 
received.  Ligands (S,S)-L* and (R,R)-L* were prepared according to a literature procedure, 
and all analytical data matched that report.1  K3PO4⋅H2O was purchased from Sigma-Aldrich; 
it is important that the mono-hydrate (1.0 equiv of water) is used.  Anhydrous MTBE (methyl 
tert-butyl ether) and i-Pr2O were purchased from Sigma-Aldrich and stored under nitrogen; 
other solvents were purified by passage through activated aluminum oxide in a solvent-
purification system.  Unless otherwise noted, all reactions were performed under an 
atmosphere of dry nitrogen.  Flash column chromatography was performed using silica gel 
(SiliaFlash® P60, particle size 40-63 µm, Silicycle). 
NMR spectra were collected on a Bruker 400 MHz or a Varian 500 MHz spectrometer at 
ambient temperature; chemical shifts (δ) are reported in ppm downfield from 
tertramethylsilane, using the solvent resonance as the internal standard.  HPLC analyses were 
carried out on an Agilent 1100 series system with Daicel CHIRALPAK® or Daicel 
CHIRALCEL® columns (4.6 × 250 mm, particle size 5 µm).  SFC analyses were carried out on 
an Agilent 1260 Infinity II system with Daicel CHIRALPAK® or Daicel CHIRALCEL® 
columns (4.6 × 250 mm, particle size 5 µm).  FT-IR measurements were carried out on a 
Thermo Scientific Nicolet iS5 FT-IR spectrometer equipped with an iD5 ATR accessory.  HR-
MS data were acquired on a Waters LCT Premier XE TOF MS in electrospray ionization (ESI+) 
mode.  GC-MS data were obtained on an Agilent 7890A GC-MS system with an Agilent 
5975C detector.  Optical-rotation data were obtained with a Jasco P-2000 polarimeter at 589 
nm, using a 100 mm pathlength cell in the solvent and at the concentration indicated.  GC 
analyses were obtained on an Agilent 6890N GC. 
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II.  Preparation of Electrophiles 
 
The yields have not been optimized. 
 
 
General Procedure 1 (GP-1): Preparation of the electrophile.2  An oven-dried 100 mL 
round-bottom flask was charged with a magnetic stir bar and either ZnCl2 or ZnBr2 (0.050 
equiv), and then it was sealed with a rubber septum cap.  The flask was placed under a 
nitrogen atmosphere by evacuating and backfilling the flask (three cycles), followed by the 
addition of DCM and the acyl bromide (1.2 equiv).  The resulting solution was cooled to –10 
°C, and the mixture was stirred for 10 min.  At this temperature, the aldehyde (1.0 equiv) was 
added via syringe pump over 30 min, and the resulting mixture was stirred for 2 h.  Then, the 
reaction mixture was filtered through a short column of neutral aluminium oxide, with a DCM 
washing.  The filtrate was concentrated under reduced pressure.  The residue was either 
purified by vacuum distillation to afford the pure product, or used directly after the 
determination of its purity by 1H NMR (CH2Br2 as the internal standard). 
 
 
 
1-Bromoethyl benzoate.  The title compound was synthesized according to GP-1 from 
ZnCl2 (544 mg, 4.0 mmol), BzBr (11.3 mL, 96.0 mmol), acetaldehyde (4.5 mL, 80 mmol), and 
DCM (10 mL).  The product was purified by vacuum distillation (b.p. = 75–79 °C, 1.2 Torr).  
9.6 g (42.1 mmol, 53% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.04 (m, 2H), 7.65 – 7.56 (m, 1H), 7.52 – 7.42 (m, 2H), 
6.97 (q, J = 5.9 Hz, 1H), 2.14 (d, J = 5.9 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 164.1, 134.0, 130.2, 128.9, 128.7, 72.4, 27.0. 
FT-IR (film): 2983, 1732, 1603, 1453, 1265, 1064, 898, 707 cm-1. 
 
 
 
1-Bromopropyl benzoate.  The title compound was synthesized according to GP-1 from 
ZnCl2 (870 mg, 6.4 mmol), BzBr (18.0 mL, 154 mmol), propionaldehyde (9.2 mL, 128 mmol), 
and DCM (20 mL).  The product was purified by vacuum distillation (b.p. = 88–90 °C, 0.5 
Torr).  22.4 g (92.6 mmol, 72% yield).  Colorless oil. 
ZnCl2 or ZnBr2
DCM, –10 °C R
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O
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1H NMR (500 MHz, CDCl3) δ 8.10 – 8.05 (m, 2H), 7.65 – 7.58 (m, 1H), 7.50 – 7.43 (m, 2H), 
6.85 (t, J = 5.7 Hz, 1H), 2.36 – 2.23 (m, 2H), 1.15 (t, J = 7.3 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 164.2, 134.0, 130.1, 129.0, 128.7, 78.3, 32.9, 10.4. 
FT-IR (film): 2980, 2941, 1732, 1602, 1453, 1261, 1066, 961, 908, 716 cm-1. 
 
 
 
1-Bromopentyl benzoate.  The title compound was synthesized according to GP-1 from 
ZnCl2 (544 mg, 4.0 mmol), BzBr (11.3 mL, 96.0 mmol), valeraldehyde (8.5 mL, 80 mmol), and 
DCM (10 mL).  The product was purified by vacuum distillation (b.p. = 103–108 °C, 0.7 Torr).  
8.4 g (31.1 mmol, 39% yield).  Yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.10 – 8.04 (m, 2H), 7.66 – 7.57 (m, 1H), 7.52 – 7.44 (m, 2H), 
6.89 (t, J = 5.9 Hz, 1H), 2.37 – 2.21 (m, 2H), 1.61 – 1.49 (m, 2H), 1.48 – 1.35 (m, 2H), 0.95 (t, J = 7.3 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 164.3, 134.0, 130.2, 129.0, 128.7, 76.8, 39.4, 28.1, 22.1, 14.0. 
FT-IR (film): 2959, 1746, 1602, 1453, 1242, 1067, 989, 708 cm-1. 
 
 
 
1-Bromo-3-methylbutyl benzoate.  The title compound was synthesized according to GP-
1 from ZnBr2 (888 mg, 4.0 mmol), BzBr (11.3 mL, 96.0 mmol), isovaleraldehyde (8.6 mL, 80 
mmol), and DCM (10 mL).  The product was purified by vacuum distillation (b.p. = 95–98 °C, 
0.7 Torr).  14.3 g (53.0 mmol, 66% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.04 (m, 2H), 7.65 – 7.57 (m, 1H), 7.53 – 7.42 (m, 2H), 
6.95 (dd, J = 7.6, 5.6 Hz, 1H), 2.28 (ddd, J = 14.2, 7.6, 6.6 Hz, 1H), 2.16 (ddd, J = 14.3, 7.3, 5.6 Hz, 
1H), 1.99 – 1.86 (m, 1H), 0.99 (d, J = 6.4 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 164.3, 134.0, 130.2, 129.0, 128.7, 76.0, 48.4, 26.1, 22.4, 22.1. 
FT-IR (film): 2962, 1735, 1602, 1452, 1260, 1067, 987, 716 cm-1. 
 
 
 
1-Bromo-3,3-dimethylbutyl benzoate.  The title compound was synthesized according to 
GP-1 from ZnCl2 (340 mg, 2.5 mmol), BzBr (7.0 mL, 60 mmol), 3,3-dimethylbutyraldehyde (5.0 
S–5 
g, 50 mmol), and DCM (8 mL).  The product was purified by vacuum distillation (b.p. = 102–
103 °C, 0.9 Torr).  9.9 g (35 mmol, 70% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.13 – 8.01 (m, 2H), 7.67 – 7.57 (m, 1H), 7.55 – 7.42 (m, 2H), 
7.07 (dd, J = 10.1, 2.2 Hz, 1H), 2.54 (dd, J = 14.8, 10.1 Hz, 1H), 2.25 (dd, J = 14.8, 2.3 Hz, 1H), 0.98 
(s, 9H). 
13C NMR (101 MHz, CDCl3) δ 164.1, 134.1, 130.2, 128.9, 128.8, 74.9, 53.4, 32.1, 29.8. 
FT-IR (film): 2956, 1738, 1602, 1454, 1246, 1063, 975, 714 cm-1. 
 
 
 
Bromo(cyclobutyl)methyl benzoate.  The title compound was synthesized according to 
GP-1 from ZnBr2 (400 mg, 1.8 mmol), BzBr (5.0 mL, 43 mmol), cyclobutanecarbaldehyde (3.0 g, 
36 mmol), and DCM (10 mL).  The product was purified by vacuum distillation (b.p. = 103–
104 °C, 0.6 Torr).  7.7 g (29 mmol, 80% yield).  Yellow solid. 
1H NMR (400 MHz, CDCl3) δ 8.13 – 8.03 (m, 2H), 7.67 – 7.58 (m, 1H), 7.53 – 7.44 (m, 2H), 
6.83 (d, J = 7.2 Hz, 1H), 3.19 – 3.07 (m, 1H), 2.17 (m, 2H), 2.10 – 1.81 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 164.5, 134.0, 130.2, 129.0, 128.7, 80.2, 42.6, 25.3, 25.1, 16.8. 
FT-IR (film): 2985, 1738, 1601, 1452, 1263, 1064, 994, 711 cm-1. 
 
 
 
Bromo(cyclohexyl)methyl benzoate.  The title compound was synthesized according to 
GP-1 from ZnBr2 (555 mg, 2.5 mmol), BzBr (7.0 mL, 60 mmol), cyclohexanecarbaldehyde (6.0 
mL, 50 mmol), and DCM (5 mL).  The product was used without further purification (98 
wt.%).  14.3 g (47.3 mmol, 95% yield).  Yellow solid. 
1H NMR (500 MHz, CDCl3) δ 8.10 – 8.04 (m, 2H), 7.65 – 7.58 (m, 1H), 7.51 – 7.44 (m, 2H), 
6.77 (d, J = 4.7 Hz, 1H), 2.06 – 1.95 (m, 3H), 1.88 – 1.80 (m, 2H), 1.76 – 1.68 (m, 1H), 1.39 – 1.15 
(m, 5H). 
13C NMR (126 MHz, CDCl3) δ 164.2, 134.0, 130.1, 129.1, 128.7, 82.3, 45.6, 29.3, 28.6, 26.2, 
25.73, 25.71. 
FT-IR (film): 2932, 1732, 1602, 1452, 1258, 1064, 962, 708 cm-1. 
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1-Bromo-2-methylpropyl benzoate.  The title compound was synthesized according to 
GP-1 from ZnCl2 (544 mg, 4.0 mmol), BzBr (11.3 mL, 96.0 mmol), isobutyraldehyde (7.3 mL, 80 
mmol), and DCM (10 mL).  The product was purified by vacuum distillation (b.p. = 88–94 °C, 
0.5 Torr).  11.9 g (46.5 mmol, 58% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.02 (m, 2H), 7.66 – 7.58 (m, 1H), 7.53 – 7.43 (m, 2H), 
6.81 (d, J = 4.2 Hz, 1H), 2.35 – 2.21 (m, 1H), 1.18 (t, J = 6.4 Hz, 3H), 1.16 (t, J = 6.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 164.2, 134.0, 130.1, 129.1, 128.7, 83.3, 36.2, 18.5, 18.4. 
FT-IR (film): 2973, 1746, 1602, 1456, 1255, 1064, 802, 680 cm-1. 
 
 
 
1-Bromo-3-phenylpropyl benzoate.  The title compound was synthesized according to 
GP-1 from ZnBr2 (555 mg, 2.5 mmol), BzBr (7.0 mL, 60 mmol), 3-phenylpropionaldehyde (6.6 
mL, 50 mmol), and DCM (10 mL).  The product was used without further purification (95 
wt.%).  13.6 g (40.6 mmol, 81% yield).  Yellow solid. 
1H NMR (400 MHz, CDCl3) δ 8.08 – 8.01 (m, 2H), 7.67 – 7.59 (m, 1H), 7.52 – 7.44 (m, 2H), 
7.37 – 7.28 (m, 2H), 7.26 – 7.19 (m, 3H), 6.87 (t, J = 5.8 Hz, 1H), 2.92 (t, J = 7.2 Hz, 2H), 2.70 – 2.55 
(m, 2H). 
13C NMR (101 MHz, CDCl3) δ 164.1, 139.9, 134.1, 130.2, 128.9, 128.8, 128.7, 128.6, 126.5, 76.3, 
41.0, 32.2. 
FT-IR (film): 3027, 1738, 1602, 1453, 1245, 1065, 919, 711 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C16H19BrNO2: 336.0594, found: 336.0604. 
 
 
 
Bromo(tetrahydro-2H-pyran-4-yl)methyl benzoate.  The title compound was synthesized 
according to GP-1 from ZnBr2 (235 mg, 1.1 mmol), BzBr (2.5 mL, 21 mmol), tetrahydro-2H-
pyran-4-carbaldehyde (2.0 g, 18 mmol), and DCM (5 mL).  The product was used without 
further purification (95 wt.%).  3.5 g (11.2 mmol, 64% yield).  Yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.03 (m, 2H), 7.66 – 7.58 (m, 1H), 7.53 – 7.43 (m, 2H), 
6.77 (d, J = 5.4 Hz, 1H), 4.12 – 4.01 (m, 2H), 3.49 – 3.37 (m, 2H), 2.36 – 2.23 (m, 1H), 1.98 – 1.80 
(m, 2H), 1.73 – 1.54 (m, 2H). 
S–7 
13C NMR (101 MHz, CDCl3) δ 164.1, 134.2, 130.2, 130.1, 128.8, 80.5, 67.42, 67.39*, 43.3, 29.5, 
28.7. 
FT-IR (film): 2951, 1732, 1602, 1451, 1258, 1064, 954, 711 cm-1. 
 
 
 
1-Bromo-6-chlorohexyl benzoate.  The title compound was synthesized according to GP-
1 from ZnBr2 (350 mg, 1.6 mmol), BzBr (4.5 mL, 38 mmol), 6-chlorohexanal (4.25 g, 31.6 mmol), 
and DCM (5 mL).  The product was used without further purification (85 wt.%).  8.9 g (24 
mmol, 75% yield).  Brown oil. 
1H NMR (400 MHz, CDCl3) δ 8.10 – 8.03 (m, 2H), 7.66 – 7.58 (m, 1H), 7.51 – 7.44 (m, 2H), 
6.89 (t, J = 5.9 Hz, 1H), 3.55 (t, J = 6.6 Hz, 2H), 2.35 – 2.25 (m, 2H), 1.89 – 1.77 (m, 2H), 1.68 – 1.50 
(m, 4H). 
13C NMR (101 MHz, CDCl3) δ 164.2, 134.1, 130.2, 128.9, 128.7, 76.7, 44.9, 39.4, 32.4, 26.2, 25.3. 
FT-IR (film): 2934, 1739, 1603, 1454, 1267, 1067, 996, 714 cm-1. 
 
 
 
1,6-Dibromohexyl benzoate.  The title compound was synthesized according to GP-1 
from ZnBr2 (390 mg, 1.8 mmol), BzBr (4.9 mL, 42 mmol), 6-bromohexanal (6.2 g, 35 mmol), and 
DCM (5 mL).  The product was used without further purification (89 wt.%).  8.9 g (22 mmol, 
63% yield).  Brown oil. 
1H NMR (500 MHz, CDCl3) δ 8.09 – 8.04 (m, 2H), 7.65 – 7.59 (m, 1H), 7.50 – 7.45 (m, 2H), 
6.89 (t, J = 5.8 Hz, 1H), 3.43 (t, J = 6.7 Hz, 2H), 2.37 – 2.24 (m, 2H), 1.95 – 1.87 (m, 2H), 1.72 – 1.44 
(m, 4H). 
13C NMR (126 MHz, CDCl3) δ 164.2, 134.1, 130.1, 128.8, 128.7, 76.7, 39.3, 33.6, 32.5, 27.4, 25.2. 
FT-IR (film): 2934, 1738, 1601, 1452, 1260, 1071, 980, 714 cm-1. 
 
 
 
(3S)-1-Bromo-3,7-dimethyloctyl benzoate.  The title compound was synthesized 
according to GP-1 from ZnBr2 (120 mg, 0.54 mmol), BzBr (1.6 mL, 13 mmol), (S)-3,7-
dimethyloctanal (1.7 g, 11 mmol), and DCM (5 mL).  The product was obtained as a mixture 
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of two diastereoisomers (~1:1) and used without further purification (62 wt.%).  3.7 g (6.7 
mmol, 62% yield).  Yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.04 (m, 2H), 7.67 – 7.57 (m, 1H), 7.53 – 7.43 (m, 2H), 
7.03 – 6.90 (m, 1H), 2.50 – 2.11 (m, 2H), 1.83 – 1.68 (m, 1H), 1.55 – 1.48 (m, 1H), 1.37 – 1.16 (m, 
6H), 0.92 – 0.80 (m, 9H). 
13C NMR (101 MHz, CDCl3) δ 164.33, 164.26, 134.02, 134.00, 130.18, 130.15, 128.73, 128.71, 
76.6, 75.7, 51.2, 47.0, 46.5, 39.2, 37.3, 37.0, 36.8, 30.8, 28.3, 28.1, 24.8, 24.6, 24.5, 22.8, 22.7, 20.1, 
19.5, 19.3. 
FT-IR (film): 2932, 1738, 1602, 1458, 1256, 1068, 993, 711 cm-1. 
 
 
 
1-Bromohexyl acetate.  The title compound was synthesized according to GP-1 from 
ZnCl2 (1.0 g, 7.5 mmol), AcBr (13.2 mL, 180 mmol), hexanal (18.4 mL, 150 mmol), and DCM (20 
mL).  The product was purified by vacuum distillation (b.p. = 58–59 °C, 1.0 Torr).  17.4 g 
(78.4 mmol, 52% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 6.59 (t, J = 6.1 Hz, 1H), 2.17 – 2.04 (m, 2H), 2.10 (s, 3H), 1.51 – 
1.39 (m, 2H), 1.39 – 1.23 (m, 4H), 0.95 – 0.81 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.6, 76.6, 39.4, 31.0, 25.6, 22.5, 21.1, 14.0. 
FT-IR (film): 2956, 1767, 1449, 1375, 1211, 1027, 944, 687 cm-1. 
 
 
 
1-Bromohexyl isobutyrate.  The title compound was synthesized according to GP-1 from 
ZnBr2 (555 mg, 2.5 mmol), isobutyryl bromide (6.4 mL, 60 mmol), hexanal (6.1 mL, 50 mmol), 
and DCM (10 mL).  The product was purified by vacuum distillation (b.p. = 50–51 °C, 0.4 
Torr).  7.2 g (29 mmol, 58% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 6.62 (t, J = 6.0 Hz, 1H), 2.69 – 2.49 (m, 1H), 2.22 – 2.06 (m, 2H), 
1.51 – 1.41 (m, 2H), 1.36 – 1.28 (m, 4H), 1.19 (d, J = 6.8 Hz, 3H), 1.18 (d, J = 6.8 Hz, 3H), 0.93 – 
0.86 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 174.7, 76.7, 39.5, 34.1, 31.0, 25.7, 22.5, 18.6, 18.5, 14.0. 
FT-IR (film): 2960, 1760, 1467, 1388, 1230, 1108, 941, 680 cm-1. 
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1-Bromopropyl pivalate.  The title compound was synthesized according to GP-1 from 
ZnCl2 (480 mg, 3.6 mmol), pivaloyl bromide (14.0 g, 85.4 mmol), propionaldehyde (5.1 mL, 71 
mmol), and DCM (10 mL).  The product was purified by vacuum distillation (b.p. = 45–47 °C, 
2.2 Torr).  6.6 g (30 mmol, 42% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 6.58 (t, J = 5.7 Hz, 1H), 2.22 – 2.08 (m, 2H), 1.21 (s, 9H), 1.04 (t, 
J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 176.0, 78.0, 39.0, 32.8, 26.8, 10.4. 
FT-IR (film): 2973, 1758, 1461, 1370, 1216, 1120, 969, 689 cm-1. 
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III.  Catalytic Enantioconvergent Couplings 
 
Although we have not encountered any safety issues, it is important to note that, under 
certain conditions, triethoxysilane has been reported to disproportionate to SiH4. 
 
General Procedure 2 (GP-2): MTBE as the solvent; electrophile is a liquid. 
In the air, NiBr2⋅diglyme (28.2 mg, 0.081 mmol, 0.10 equiv), (S,S)-L* (61.2 mg, 0.096 mmol, 
0.12 equiv), and K3PO4⋅H2O (552 mg, 2.4 mmol, 3.0 equiv) were added to an oven-dried 40 mL 
vial equipped with a cross stir bar.  The vial was closed with a PTFE septum cap, the joint 
was wrapped with electrical tape, and the vial was placed under a nitrogen atmosphere by 
evacuating and backfilling the vial (three cycles).  Anhydrous MTBE (8.0 mL) was added to 
the vial, and the mixture was stirred at room temperature for 30 min, at which time it was a 
pink heterogeneous solution.  A balloon filled with nitrogen was attached to the reaction vial.  
Next, the electrophile (0.80 mmol, 1.0 equiv), olefin (2.4 mmol, 3.0 equiv), and triethoxysilane 
(440 µL, 2.4 mmol, 3.0 equiv) were added dropwise in turn to the reaction mixture.  The 
balloon was removed, and the septum cap was sealed with vacuum grease.  The mixture was 
stirred vigorously (1100 rpm) at room temperature for 20 h. 
Work-up: The reaction mixture was passed through a plug of silica gel, and the vial, the 
cap, and the silica gel were rinsed with Et2O.  The filtrate was concentrated, and the residue 
was purified by flash chromatography on silica gel. 
 
General Procedure 3 (GP-3): MTBE as the solvent; electrophile is a solid. 
In the air, NiBr2⋅diglyme (28.2 mg, 0.081 mmol, 0.10 equiv), (S,S)-L* (61.2 mg, 0.096 mmol, 
0.12 equiv), and K3PO4⋅H2O (552 mg, 2.4 mmol, 3.0 equiv) were added to an oven-dried 40 mL 
vial equipped with a cross stir bar.  The vial was closed with a PTFE septum cap, the joint 
was wrapped with electrical tape, and the vial was placed under a nitrogen atmosphere by 
evacuating and backfilling the vial (three cycles).  Anhydrous MTBE (4.0 mL) was added to 
the vial, and the mixture was stirred at room temperature for 30 min, at which time it was a 
pink heterogeneous solution.  A balloon filled with nitrogen was attached to the reaction vial. 
Next, in the air, a separate oven-dried 20 mL vial was charged with the electrophile (0.80 
mmol, 1.0 equiv).  The vial was capped with a PTFE septum cap, and then it was evacuated 
and backfilled with nitrogen (three cycles).  Anhydrous MTBE (4.0 mL) was added to this vial 
to dissolve the solid.  Next, this solution of the electrophile was added in one portion via 
syringe to the catalyst solution, followed by the addition of olefin (2.4 mmol, 3.0 equiv) and 
triethoxysilane (440 µL, 2.4 mmol, 3.0 equiv).  The balloon was removed, and the septum cap 
was sealed with vacuum grease.  The mixture was stirred vigorously (1100 rpm) at room 
temperature for 20 h. 
Work-up: Same as GP-2. 
 
General Procedure 4 (GP-4): i-Pr2O as the solvent; electrophile is a liquid. 
In the air, NiBr2⋅diglyme (28.2 mg, 0.081 mmol, 0.10 equiv), (S,S)-L* (61.2 mg, 0.096 mmol, 
0.12 equiv), and K3PO4⋅H2O (368 mg, 1.6 mmol, 2.0 equiv) were added to an oven-dried 40 mL 
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vial equipped with a cross stir bar.  The vial was closed with a PTFE septum cap, the joint 
was wrapped with electrical tape, and the vial was placed under a nitrogen atmosphere by 
evacuating and backfilling the vial (three cycles).  Anhydrous i-Pr2O (4.0 mL) was added to 
the vial, and the mixture was stirred at room temperature for 30 min, at which time it was a 
yellow heterogeneous solution.  A balloon filled with nitrogen was attached to the reaction 
vial.  Next, the electrophile (0.80 mmol, 1.0 equiv), olefin (2.4 mmol, 3.0 equiv), and 
triethoxysilane (300 µL, 1.6 mmol, 2.0 equiv) were added dropwise in turn to the reaction 
mixture.  The balloon was removed, and the septum cap was sealed with vacuum grease.  
The mixture was stirred vigorously (1100 rpm) at room temperature for 20 h. 
Work-up: Same as GP-2. 
 
General Procedure 5 (GP-5): Determination of enantioselectivity by converting the 
benzoate product to the corresponding phosphate.  In the air, NaOH (48.0 mg, 1.2 mmol, 6.0 
equiv) was added to a solution of the benzoate product (0.20 mmol, 1.0 equiv) in MeOH (6 
mL).  The reaction mixture was stirred at 50 °C for 24 h, and then the solvent was evaporated, 
and water (5 mL) was added to the residue.  The reaction mixture was extracted with Et2O (10 
mL x 3).  The combined organic layers were dried over Na2SO4, filtered, and concentrated to 
afford the alcohol, which was used directly without further purification.  In the air, diphenyl 
phosphoryl chloride (83 µL, 0.38 mmol, 1.9 equiv) was added to a solution of the alcohol and 
DMAP (48.8 mg, 0.40 mmol, 2.0 equiv) in DCM (4 mL), and then the reaction mixture was 
stirred at room temperature for 3 h.  The reaction mixture was concentrated, and the residue 
was purified by flash chromatography on silica gel. 
 
 
 
4-Cyclohexylbutan-2-yl benzoate (Figure 3, entry 1).  The title compound was 
synthesized according to GP-2 from 1-bromoethyl benzoate and vinylcyclohexane.  The 
product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L*: 169 mg, 81% yield, 92% ee; (R,R)-L*: 171 mg, 82% yield, 93% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (0.5% i-
PrOH in hexane, 0.5 mL/min); retention times for compound obtained using (S,S)-L*: 12.5 min 
(major), 13.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.08 – 8.01 (m, 2H), 7.58 – 7.51 (m, 1H), 7.48 – 7.39 (m, 2H), 
5.18 – 5.08 (m, 1H), 1.81 – 1.56 (m, 7H), 1.33 (d, J = 6.3 Hz, 3H), 1.32 – 1.06 (m, 6H), 0.95 – 0.80 
(m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.4, 132.8, 131.1, 129.6, 128.4, 72.2, 37.7, 33.52, 33.45, 33.2, 
26.8, 26.5, 20.2. 
FT-IR (film): 2929, 1716, 1603, 1451, 1276, 1110, 711 cm-1. 
S–12 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C17H28NO2: 278.2115, found: 278.2114. 
[α]23D = −28 (c 1.0, CHCl3); 92% ee, from (S,S)-L*. 
 
 
 
1-Cyclohexylpentan-3-yl benzoate (Figure 3, entry 2).  The title compound was 
synthesized according to GP-2 from 1-bromopropyl benzoate and vinylcyclohexane.  The 
product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L*: 172 mg, 78% yield, 92% ee; (R,R)-L*: 175 mg, 80% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (0.5% i-
PrOH in hexane, 0.5 mL/min); retention times for compound obtained using (S,S)-L*: 11.5 min 
(major), 12.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.09 – 8.03 (m, 2H), 7.59 – 7.52 (m, 1H), 7.49 – 7.40 (m, 2H), 
5.11 – 5.01 (m, 1H), 1.78 – 1.58 (m, 9H), 1.33 – 1.06 (m, 6H), 0.95 (t, J = 7.5 Hz, 3H), 0.92 – 0.79 
(m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.8, 131.0, 129.7, 128.4, 76.6, 37.8, 33.5, 33.4, 33.1, 31.1, 
27.1, 26.8, 26.48, 26.46, 9.8. 
FT-IR (film): 2920, 1716, 1602, 1450, 1276, 1111, 712 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C18H30NO2: 292.2271, found: 292.2275. 
[α]23D = −8.4 (c 1.0, CHCl3); 92% ee, from (S,S)-L*. 
 
 
 
1-Cyclohexylheptan-3-yl benzoate (Figure 3, entry 3).  The title compound was 
synthesized according to GP-2 from 1-bromopentyl benzoate and vinylcyclohexane.  The 
product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L*: 189 mg, 78% yield, 94% ee; (R,R)-L*: 186 mg, 77% yield, 92% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.08 – 8.02 (m, 2H), 7.59 – 7.52 (m, 1H), 7.48 – 7.40 (m, 2H), 
5.15 – 5.06 (m, 1H), 1.77 – 1.58 (m, 9H), 1.42 – 1.29 (m, 4H), 1.29 – 1.08 (m, 6H), 0.94 – 0.78 (m, 
5H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.8, 131.0, 129.7, 128.4, 75.5, 37.8, 34.0, 33.5, 33.4, 33.1, 
31.7, 27.7, 26.8, 26.49, 26.48, 22.8, 14.2. 
S–13 
FT-IR (film): 2921, 1715, 1603, 1453, 1274, 1114, 711 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C20H34NO2: 320.2584, found: 320.2583. 
[α]23D = −2.2 (c 1.0, CHCl3); 94% ee, from (S,S)-L*. 
 
 
 
1-Cyclohexylheptan-3-yl diphenyl phosphate.  The title compound was synthesized 
according to GP-5.  The product was purified by column chromatography on silica gel (1:5 
EtOAc/hexanes).  Colorless oil. 
(S,S)-L*: 81.6 mg, 95% yield, 94% ee; (R,R)-L*: 78.9 mg, 92% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 12.5 min 
(major), 13.8 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 4H), 7.28 – 7.22 (m, 4H), 7.18 (t, J = 7.3 Hz, 2H), 
4.73 – 4.55 (m, 1H), 1.74 – 1.56 (m, 9H), 1.38 – 1.10 (m, 10H), 0.91 – 0.74 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 7.1 Hz), 129.7, 125.2, 120.2 (d, J = 5.1 Hz), 82.8 (d, J 
= 7.1 Hz), 37.6, 34.7 (d, J = 5.1 Hz), 33.3, 33.2, 32.4, 32.33, 32.30, 26.9, 26.7, 26.4 (d, J = 1.0 Hz), 
22.6, 14.0. 
31P NMR (162 MHz, CDCl3) δ –12.4. 
FT-IR (film): 2931, 1594, 1488, 1288, 1192, 1022, 768 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C25H39NO4P: 448.2611, found: 448.2621. 
[α]23D = +1.9 (c 1.0, CHCl3); 94% ee, from (S,S)-L*. 
 
 
 
1-Cyclohexyl-5-methylhexan-3-yl benzoate (Figure 3, entry 4).  The title compound was 
synthesized according to GP-2 from 1-bromo-3-methylbutyl benzoate and vinylcyclohexane.  
The product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 197 mg, 82% yield, 95% ee; (R,R)-L*: 202 mg, 84% yield, 95% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.12 – 7.96 (m, 2H), 7.63 – 7.50 (m, 1H), 7.50 – 7.37 (m, 2H), 
5.28 – 5.15 (m, 1H), 1.75 – 1.58 (m, 9H), 1.46 – 1.36 (m, 1H), 1.30 – 1.08 (m, 6H), 0.93 (d, J = 6.3 
Hz, 6H), 0.91 – 0.79 (m, 2H). 
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13C NMR (101 MHz, CDCl3) δ 166.5, 132.8, 131.0, 129.7, 128.4, 73.9, 43.5, 37.8, 33.5, 33.4, 33.0, 
32.3, 26.8, 26.49, 26.48, 24.0, 23.4, 22.4. 
FT-IR (film): 2927, 1715, 1602, 1455, 1274, 1114, 713 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C20H34NO2: 320.2584, found: 320.2574. 
[α]23D = +7.8 (c 1.0, CHCl3); 95% ee, from (S,S)-L*. 
 
 
 
1-Cyclohexyl-5-methylhexan-3-yl diphenyl phosphate.  The title compound was 
synthesized according to GP-5.  The product was purified by column chromatography on 
silica gel (1:5 EtOAc/hexanes).  Colorless oil. 
(S,S)-L*: 79.0 mg, 92% yield, 95% ee; (R,R)-L*: 79.0 mg, 92% yield, 95% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 11.9 min 
(minor), 15.2 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.29 (m, 4H), 7.27 – 7.20 (m, 4H), 7.20 – 7.13 (m, 2H), 
4.74 – 4.63 (m, 1H), 1.74 – 1.56 (m, 9H), 1.41 – 1.30 (m, 1H), 1.25 – 1.05 (m, 6H), 0.94 – 0.74 (m, 
8H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 7.1 Hz), 129.7 (d, J = 1.0 Hz), 125.2 (d, J = 1.0 Hz), 
120.2 (d, J = 5.1 Hz), 81.2 (d, J = 6.1 Hz), 44.2 (d, J = 6.1 Hz), 37.6, 33.3, 33.2, 33.1, 33.0, 32.1, 26.7, 
26.4 (d, J = 1.0 Hz), 24.4, 23.1, 22.2. 
31P NMR (162 MHz, CDCl3) δ –12.4. 
FT-IR (film): 2924, 1591, 1490, 1286, 1197, 1020, 762 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C25H39NO4P: 448.2611, found: 448.2619. 
[α]23D = +10.8 (c 1.0, CHCl3); 95% ee, from (S,S)-L*. 
 
 
 
1-Cyclohexyl-5,5-dimethylhexan-3-yl benzoate (Figure 3, entry 5).  The title compound 
was synthesized according to GP-2 from 1-bromo-3,3-dimethylbutyl benzoate and 
vinylcyclohexane.  The product was purified by column chromatography on silica gel (1:40 
Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 217 mg, 86% yield, 94% ee; (R,R)-L*: 209 mg, 83% yield, 94% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
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1H NMR (400 MHz, CDCl3) δ 8.08 – 8.01 (m, 2H), 7.58 – 7.51 (m, 1H), 7.47 – 7.40 (m, 2H), 
5.28 – 5.20 (m, 1H), 1.78 – 1.56 (m, 8H), 1.48 (dd, J = 14.8, 2.2 Hz, 1H), 1.27 – 1.07 (m, 6H), 0.93 
(s, 9H), 0.90 – 0.79 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.3, 132.8, 131.1, 129.7, 128.4, 73.2, 47.6, 37.9, 33.8, 33.5, 33.4, 
32.8, 30.3, 30.1, 26.8, 26.5. 
FT-IR (film): 2931, 1714, 1604, 1454, 1272, 1118, 709 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C21H36NO2: 334.2741, found: 334.2750. 
[α]23D = +13.8 (c 1.0, CHCl3); 94% ee, from (S,S)-L*. 
 
 
 
1-Cyclohexyl-5,5-dimethylhexan-3-yl diphenyl phosphate.  The title compound was 
synthesized according to GP-5.  The product was purified by column chromatography on 
silica gel (1:5 EtOAc/hexanes).  Colorless oil. 
(S,S)-L*: 69.6 mg, 78% yield, 94% ee; (R,R)-L*: 74.4 mg, 83% yield, 94% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 11.2 min 
(minor), 15.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 4H), 7.27 – 7.22 (m, 4H), 7.22 – 7.14 (m, 2H), 
4.85 – 4.69 (m, 1H), 1.78 – 1.58 (m, 8H), 1.53 – 1.44 (m, 1H), 1.31 – 1.06 (m, 6H), 0.95 (s, 9H), 0.89 
– 0.74 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 150.8 (d, J = 7.1 Hz), 129.7 (d, J = 1.0 Hz), 125.1 (d, J = 2.0 Hz), 
120.3 (d, J = 2.0 Hz), 120.2 (d, J = 2.0 Hz), 80.7 (d, J = 7.1 Hz), 48.4 (d, J = 7.1 Hz), 37.7, 34.7 (d, J = 
2.0 Hz), 33.33, 33.26, 32.0, 30.1, 29.9, 26.7, 26.4. 
31P NMR (162 MHz, CDCl3) δ –12.9. 
FT-IR (film): 2938, 1596, 1495, 1288, 1202, 1010, 779 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C26H41NO4P: 462.2768, found: 462.2769. 
[α]23D = +13.9 (c 1.0, CHCl3); 94% ee, from (S,S)-L*. 
 
 
 
1-Cyclobutyl-3-cyclohexylpropyl benzoate (Figure 3, entry 6).  The title compound was 
synthesized according to GP-3 from bromo(cyclobutyl)methyl benzoate and vinylcyclohexane.  
The product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  
Colorless oil. 
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(S,S)-L*: 195 mg, 81% yield, 98% ee; (R,R)-L*: 190 mg, 79% yield, 98% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.10 – 8.04 (m, 2H), 7.59 – 7.53 (m, 1H), 7.49 – 7.41 (m, 2H), 
5.11 (q, J = 6.4 Hz, 1H), 2.68 – 2.54 (m, 1H), 2.07 – 1.91 (m, 3H), 1.91 – 1.73 (m, 3H), 1.73 – 1.50 
(m, 7H), 1.29 – 1.02 (m, 6H), 0.93 – 0.76 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.7, 132.8, 131.0, 129.7, 128.4, 78.1, 39.3, 37.8, 33.5, 33.4, 33.1, 
29.5, 26.8, 26.49, 26.47, 24.7, 24.4, 18.2. 
FT-IR (film): 2921, 1716, 1603, 1451, 1263, 1114, 708 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C20H28NaO2: 323.1982, found: 323.1966. 
[α]23D = −4.0 (c 1.0, CHCl3); 98% ee, from (S,S)-L*. 
Gram-scale reaction: In the air, NiBr2⋅diglyme (176 mg, 0.50 mmol, 0.10 equiv), (S,S)-L* 
(383 mg, 0.60 mmol, 0.12 equiv), and K3PO4⋅H2O (3.45 g, 15.0 mmol, 3.0 equiv) were added to 
an oven-dried 100 mL round-bottom flask equipped with a stir bar.  The flask was closed 
with a rubber septum cap, the joint was wrapped with electrical tape, and the flask was placed 
under a nitrogen atmosphere by evacuating and backfilling the flask (three cycles).  
Anhydrous MTBE (20 mL) was added to the flask, and the mixture was stirred at room 
temperature for 30 min, at which time it was a pink heterogeneous solution.  A balloon filled 
with nitrogen was attached to the reaction flask.  In the air, a separate oven-dried 40 mL vial 
was charged with bromo(cyclobutyl)methyl benzoate (1.34 g, 5.0 mmol, 1.0 equiv).  The vial 
was capped with a PTFE septum cap, and then it was evacuated and backfilled with nitrogen 
(three cycles).  Anhydrous MTBE (20 mL) was added to the vial to dissolve the electrophile.  
Next, this solution of the electrophile was added in one portion via syringe to the catalyst 
solution, followed by the addition of vinyl cyclohexane (2.05 mL, 15.0 mmol, 3.0 equiv) and 
triethoxysilane (2.8 mL, 15.2 mmol, 3.0 equiv).  The balloon was removed, and the septum 
was sealed with electrical tape.  The reaction mixture was stirred vigorously (1100 rpm) at 
room temperature for 20 h.  Next, the reaction mixture was passed through a 5 cm column of 
silica gel, and the flask, the septum, and the silica gel were rinsed with Et2O.  The filtrate was 
concentrated, and the residue was purified by flash chromatography on silica gel (1:40 
Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 1.21 g, 81% yield, 99% ee. 
 
 
 
1-Cyclobutyl-3-cyclohexylpropyl diphenyl phosphate.  The title compound was 
synthesized according to GP-5.  The product was purified by column chromatography on 
silica gel (1:5 EtOAc/hexanes).  Colorless oil. 
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(S,S)-L*: 76.8 mg, 90% yield, 98% ee; (R,R)-L*: 70.4 mg, 82% yield, 98% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 7.8 min 
(major), 8.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.28 (m, 4H), 7.26 – 7.20 (m, 4H), 7.20 – 7.13 (m, 2H), 
4.60 – 4.49 (m, 1H), 2.65 – 2.50 (m, 1H), 2.03 – 1.76 (m, 5H), 1.72 – 1.48 (m, 8H), 1.24 – 1.04 (m, 
6H), 0.86 – 0.69 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 150.94 (d, J = 7.1 Hz), 150.93 (d, J = 7.1 Hz), 129.7, 125.2 (d, J = 
1.0 Hz), 120.3 (d, J = 2.0 Hz), 120.2 (d, J = 1.0 Hz), 86.1 (d, J = 7.1 Hz), 39.5 (d, J = 5.1 Hz), 37.6, 
33.4, 33.1, 32.2, 30.4, 30.3, 26.7, 26.4 (d, J = 2.0 Hz), 24.8, 24.4, 17.8. 
31P NMR (162 MHz, CDCl3) δ –12.1. 
FT-IR (film): 3483, 2922, 1596, 1488, 1286, 1204, 1016, 756 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C25H37NO4P: 446.2455, found: 446.2461. 
[α]23D = +3.9 (c 1.0, CHCl3); 98% ee, from (S,S)-L*. 
 
 
 
1,3-Dicyclohexylpropyl benzoate (Figure 3, entry 7).  The title compound was 
synthesized according to GP-3 from bromo(cyclohexyl)methyl benzoate and vinylcyclohexane.  
The product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 178 mg, 68% yield, 96% ee; (R,R)-L*: 186 mg, 71% yield, 95% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.09 – 8.02 (m, 2H), 7.58 – 7.51 (m, 1H), 7.45 (t, J = 7.7 Hz, 2H), 
4.99 (q, J = 6.0 Hz, 1H), 1.84 – 1.58 (m, 13H), 1.29 – 1.05 (m, 11H), 0.94 – 0.76 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.8, 131.0, 129.7, 128.4, 79.1, 41.5, 37.8, 33.5, 33.3, 33.2, 
29.3, 28.7, 28.2, 26.8, 26.6, 26.48, 26.46, 26.32, 26.26. 
FT-IR (film): 2937, 1716, 1602, 1454, 1270, 713 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C22H36NO2: 346.2741, found: 346.2722. 
[α]23D = −7.8 (c 1.0, CHCl3); 96% ee, from (S,S)-L*. 
 
 
 
1,3-Dicyclohexylpropyl diphenyl phosphate.  The title compound was synthesized 
according to GP-5.  The product was purified by column chromatography on silica gel (1:5 
EtOAc/hexanes).  Colorless oil. 
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(S,S)-L*: 75.4 mg, 83% yield, 96% ee; (R,R)-L*: 69.2 mg, 76% yield, 95% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AS column (5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 6.3 min 
(minor), 10.7 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.30 (m, 4H), 7.27 – 7.22 (m, 4H), 7.21 – 7.15 (m, 2H), 
4.45 (ddd, J = 12.0, 7.2, 4.9 Hz, 1H), 1.79 – 1.56 (m, 13H), 1.29 – 1.00 (m, 11H), 0.89 – 0.72 (m, 
2H). 
13C NMR (101 MHz, CDCl3) δ 151.0 (d, J = 7.1 Hz), 150.9 (d, J = 8.1 Hz), 129.7, 125.16 (d, J = 
2.0 Hz), 125.15 (d, J = 1.0 Hz), 120.3 (d, J = 5.1 Hz), 120.2 (d, J = 5.1 Hz), 86.9 (d, J = 7.1 Hz), 41.7 
(d, J = 5.1 Hz), 37.6, 33.4, 33.1, 32.5, 29.2 (d, J = 4.0 Hz), 28.4, 27.9, 26.7, 26.42, 26.40, 26.38, 26.2, 
26.1. 
31P NMR (162 MHz, CDCl3) δ –12.2. 
FT-IR (film): 2925, 1592, 1494, 1292, 1191, 1010, 768 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C27H41NO4P: 474.2768, found: 474.2768. 
[α]23D = −7.6 (c 1.0, CHCl3); 96% ee, from (S,S)-L*. 
 
 
 
1-Cyclohexyl-4-methylpentan-3-yl benzoate (Figure 3, entry 8).  The title compound was 
synthesized according to GP-2 from 1-bromo-2-methylpropyl benzoate and vinylcyclohexane.  
The product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 161 mg, 70% yield, 94% ee; (R,R)-L*: 154 mg, 67% yield, 95% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (0.5% i-
PrOH in hexane, 0.5 mL/min); retention times for compound obtained using (S,S)-L*: 10.2 min 
(major), 11.2 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.15 – 7.96 (m, 2H), 7.64 – 7.51 (m, 1H), 7.50 – 7.38 (m, 2H), 
4.98 (dt, J = 7.1, 5.3 Hz, 1H), 2.05 – 1.88 (m, 1H), 1.78 – 1.55 (m, 7H), 1.27 – 1.07 (m, 6H), 0.97 (t, J 
= 7.0 Hz, 6H), 0.92 – 0.76 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.6, 132.8, 131.0, 129.7, 128.4, 79.6, 37.8, 33.5, 33.4, 33.3, 31.6, 
28.7, 26.8, 26.49, 26.47, 18.9, 17.7. 
FT-IR (film): 2922, 1715, 1602, 1452, 1270, 1110, 709 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C19H28NaO2: 311.1982, found: 311.1984. 
[α]23D = −8.1 (c 1.0, CHCl3); 94% ee, from (S,S)-L*. 
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1-Cyclohexyl-5-phenylpentan-3-yl benzoate (Figure 3, entry 9).  The title compound was 
synthesized according to GP-3 from 1-bromo-3-phenylpropyl benzoate and vinylcyclohexane.  
The product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 217 mg, 78% yield, 92% ee; (R,R)-L*: 219 mg, 78% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (1% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 5.1 min 
(major), 5.8 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.05 (m, 2H), 7.61 – 7.54 (m, 1H), 7.51 – 7.42 (m, 2H), 
7.32 – 7.25 (m, 2H), 7.23 – 7.15 (m, 3H), 5.24 – 5.14 (m, 1H), 2.82 – 2.63 (m, 2H), 2.14 – 1.93 (m, 
2H), 1.84 – 1.58 (m, 7H), 1.37 – 1.06 (m, 6H), 0.97 – 0.79 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 141.8, 132.9, 130.8, 129.7, 128.53, 128.45, 126.0, 75.0, 37.7, 
36.1, 33.43, 33.40, 32.9, 31.9, 31.7, 26.8, 26.5. 
FT-IR (film): 2928, 1716, 1603, 1455, 1276, 1111, 716 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C24H34NO2: 368.2584, found: 368.2584. 
[α]23D = +5.6 (c 1.0, CHCl3); 92% ee, from (S,S)-L*. 
 
 
 
3-Cyclohexyl-1-(tetrahydro-2H-pyran-4-yl)propyl benzoate (Figure 3, entry 10).  The title 
compound was synthesized according to GP-2 from bromo(tetrahydro-2H-pyran-4-yl)methyl 
benzoate and vinylcyclohexane.  The product was purified by column chromatography on 
silica gel (1:4 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 184 mg, 70% yield, 97% ee; (R,R)-L*: 177 mg, 67% yield, 96% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (3% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 9.3 min 
(major), 12.1 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.16 – 7.99 (m, 2H), 7.60 – 7.53 (m, 1H), 7.49 – 7.42 (m, 2H), 
5.02 (q, J = 6.1 Hz, 1H), 4.09 – 3.90 (m, 2H), 3.45 – 3.28 (m, 2H), 1.96 – 1.82 (m, 1H), 1.73 – 1.42 
(m, 11H), 1.31 – 1.04 (m, 6H), 0.93 – 0.77 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 133.0, 130.6, 129.7, 128.5, 78.0, 68.1, 67.9, 38.9, 37.8, 33.5, 
33.3, 33.0, 29.3, 28.5, 28.2, 26.7, 26.5, 26.4. 
FT-IR (film): 2920, 1715, 1602, 1454, 1274, 710 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H31O3: 331.2268, found: 331.2267. 
S–20 
[α]23D = −9.8 (c 1.0, CHCl3); 97% ee, from (S,S)-L*. 
 
 
 
8-Chloro-1-cyclohexyloctan-3-yl benzoate (Figure 3, entry 11).  The title compound was 
synthesized according to GP-2 from 1-bromo-6-chlorohexyl benzoate and vinylcyclohexane.  
The product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 199 mg, 71% yield, 92% ee; (R,R)-L*: 196 mg, 70% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (1% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 6.3 min 
(minor), 7.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 8.09 – 8.00 (m, 2H), 7.60 – 7.52 (m, 1H), 7.49 – 7.40 (m, 2H), 
5.15 – 5.06 (m, 1H), 3.51 (t, J = 6.7 Hz, 2H), 1.81 – 1.60 (m, 11H), 1.53 – 1.33 (m, 4H), 1.30 – 1.09 
(m, 6H), 0.96 – 0.78 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.9, 130.9, 129.7, 128.5, 75.3, 45.1, 37.7, 34.2, 33.5, 33.4, 
33.1, 32.6, 31.7, 27.0, 26.8, 26.47, 26.46, 24.8. 
FT-IR (film): 2922, 1716, 1603, 1450, 1278, 1114, 710 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C21H35ClNO2: 368.2351, found: 368.2353. 
[α]23D = +0.86 (c 1.0, CHCl3); 92% ee, from (S,S)-L*. 
 
 
 
8-Bromo-1-cyclohexyloctan-3-yl benzoate (Figure 3, entry 12).  The title compound was 
synthesized according to GP-2 from 1,6-dibromohexyl benzoate and vinylcyclohexane.  The 
product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L*: 204 mg, 65% yield, 94% ee; (R,R)-L*: 204 mg, 65% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (0.5% i-
PrOH in hexane, 0.5 mL/min); retention times for compound obtained using (S,S)-L*: 14.4 min 
(major), 16.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.14 – 7.98 (m, 2H), 7.65 – 7.51 (m, 1H), 7.51 – 7.39 (m, 2H), 
5.20 – 5.03 (m, 1H), 3.38 (t, J = 6.8 Hz, 2H), 1.91 – 1.80 (m, 2H), 1.76 – 1.57 (m, 9H), 1.52 – 1.32 
(m, 4H), 1.32 – 1.05 (m, 6H), 0.94 – 0.78 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.9, 130.9, 129.7, 128.5, 75.3, 37.7, 34.1, 33.9, 33.5, 33.4, 
33.1, 32.8, 31.7, 28.3, 26.8, 26.47, 26.46, 24.7. 
S–21 
FT-IR (film): 2930, 1715, 1602, 1449, 1272, 1113, 710 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C21H35BrNO2: 412.1846, found: 412.1845. 
[α]23D = +1.1 (c 1.0, CHCl3); 94% ee, from (S,S)-L*. 
 
 
 
(5S)-1-Cyclohexyl-5,9-dimethyldecan-3-ol (Figure 3, entries 13 and 14).  The title 
compound was synthesized according to GP-2 and GP-5 (the benzoates could not be properly 
purified) from (3S)-1-bromo-3,7-dimethyloctyl benzoate and vinylcyclohexane.  The product 
was purified by column chromatography on silica gel (1:9 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 167 mg, 78% yield, 4:96 d.r.; (R,R)-L*: 169 mg, 79% yield, 96:4 d.r. 
HPLC analysis: The d.r. was determined after transforming the product to the 
corresponding phosphate. 
NMR data for the product from (S,S)-L*: 
1H NMR (400 MHz, CDCl3) δ 3.70 – 3.59 (m, 1H), 1.77 – 1.57 (m, 6H), 1.57 – 1.37 (m, 4H), 
1.36 – 1.09 (m, 14H), 0.95 – 0.80 (m, 11H). 
13C NMR (101 MHz, CDCl3) δ 70.2, 45.2, 39.4, 38.3, 38.0, 35.8, 33.6, 33.54, 33.47, 29.4, 28.1, 
26.8, 26.54, 26.52, 24.9, 22.84, 22.76, 19.4. 
NMR data for the product from (R,R)-L*: 
1H NMR (400 MHz, CDCl3) δ 3.72 – 3.58 (m, 1H), 1.76 – 1.42 (m, 8H), 1.39 – 1.11 (m, 15H), 
1.10 – 1.01 (m, 1H), 0.96 – 0.79 (m, 11H). 
13C NMR (101 MHz, CDCl3) δ 70.5, 45.4, 39.5, 37.9, 37.0, 35.2, 33.7, 33.44, 33.36, 29.8, 28.1, 
26.8, 26.54, 26.52, 24.7, 22.9, 22.7, 20.6. 
FT-IR (film): 3341, 2920, 1717, 1456, 1070 cm-1. 
HRMS (ESI-MS) m/z [M-OH]+ calcd for C18H35: 251.2733, found: 251.2727. 
[α]23D = +9.4 (c 1.0, CHCl3); 4:96 d.r., from (S,S)-L*. 
[α]23D = −5.7 (c 1.0, CHCl3); 96:4 d.r., from (R,R)-L*. 
 
 
 
(5S)-1-Cyclohexyl-5,9-dimethyldecan-3-yl diphenyl phosphate.  The title compound was 
synthesized according to GP-5.  The product was purified by column chromatography on 
silica gel (1:5 EtOAc/hexanes).  Colorless oil. 
(S,S)-L*: 102 mg, 99% yield, 4:96 d.r.; (R,R)-L*: 99.4 mg, 99% yield, 96:4 d.r. 
HPLC analysis: The d.r. was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 8.1 min 
(minor), 10.5 min (major). 
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NMR data for the product from (S,S)-L*: 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 4H), 7.26 – 7.20 (m, 4H), 7.20 – 7.13 (m, 2H), 
4.79 – 4.63 (m, 1H), 1.78 – 1.57 (m, 8H), 1.57 – 1.41 (m, 2H), 1.33 – 1.01 (m, 13H), 0.94 – 0.71 (m, 
11H). 
13C NMR (101 MHz, CDCl3) δ 150.93 (d, J = 7.1 Hz), 150.92 (d, J = 7.1 Hz), 129.8, 125.2, 120.3 
(d, J = 4.0 Hz), 120.2 (d, J = 5.1 Hz), 81.2 (d, J = 7.1 Hz), 42.7 (d, J = 6.1 Hz), 39.3, 37.8, 37.7, 33.50, 
33.47, 33.34, 33.26, 32.3, 29.0, 28.1, 26.7, 26.4, 24.7, 22.8, 22.7, 19.4. 
31P NMR (162 MHz, CDCl3) δ –12.4. 
NMR data for the product from (R,R)-L*: 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.28 (m, 4H), 7.26 – 7.20 (m, 4H), 7.20 – 7.13 (m, 2H), 
4.77 – 4.64 (m, 1H), 1.73 – 1.57 (m, 7H), 1.57 – 1.42 (m, 4H), 1.37 – 1.00 (m, 12H), 0.92 – 0.77 (m, 
11H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 7.1 Hz), 129.8, 125.2 (d, J = 1.0 Hz), 120.2 (d, J = 5.1 
Hz), 81.3 (d, J = 7.1 Hz), 42.5 (d, J = 5.1 Hz), 39.3, 37.6, 37.0, 33.4, 33.2, 32.64, 32.60, 32.0, 29.3, 
28.1, 26.7, 26.4 (d, J = 2.0 Hz), 24.6, 22.8, 22.7, 20.0. 
31P NMR (162 MHz, CDCl3) δ –12.4. 
FT-IR (film): 2926, 2365, 1594, 1486, 1384, 1287, 1017, 770, 688 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C30H49NO4P: 518.3394, found: 518.3392. 
[α]23D = +11.9 (c 1.0, CHCl3); 4:96 d.r., from (S,S)-L*. 
[α]23D = −8.6 (c 1.0, CHCl3); 96:4 d.r., from (R,R)-L*. 
 
 
 
12-Phenoxydodecan-6-yl acetate (Figure 3, entry 15).  The title compound was 
synthesized according to GP-4 from 1-bromohexyl acetate and (hex-5-en-1-yloxy)benzene.  
The product was purified by column chromatography on silica gel (1:9 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 162 mg, 63% yield, 93% ee; (R,R)-L*: 167 mg, 65% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 10.8 min 
(minor), 14.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.23 (m, 2H), 6.96 – 6.86 (m, 3H), 4.94 – 4.82 (m, 1H), 
3.95 (t, J = 6.5 Hz, 2H), 2.04 (s, 3H), 1.83 – 1.71 (m, 2H), 1.59 – 1.41 (m, 6H), 1.40 – 1.18 (m, 10H), 
0.95 – 0.81 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.1, 159.2, 129.5, 120.6, 114.6, 74.5, 67.9, 34.21, 34.18, 31.9, 
29.4, 29.3, 26.1, 25.4, 25.1, 22.7, 21.4, 14.2. 
FT-IR (film): 2928, 1732, 1601, 1496, 1373, 1243, 754 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C20H32NaO3: 343.2244, found: 343.2245. 
[α]23D = +1.5 (c 1.0, CHCl3); 93% ee, from (S,S)-L*. 
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12-Phenoxydodecan-6-yl isobutyrate (Figure 3, entry 16).  The title compound was 
synthesized according to GP-4 from 1-bromohexyl isobutyrate and (hex-5-en-1-yloxy)benzene.  
The product was purified by column chromatography on silica gel (1:25 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 166 mg, 60% yield, 94% ee; (R,R)-L*: 170 mg, 61% yield, 95% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (0.5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 8.5 min 
(major), 10.0 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.22 (m, 2H), 7.00 – 6.82 (m, 3H), 4.93 – 4.81 (m, 1H), 
3.94 (t, J = 6.5 Hz, 2H), 2.52 (hept, J = 7.0 Hz, 1H), 1.86 – 1.72 (m, 2H), 1.57 – 1.41 (m, 6H), 1.39 – 
1.23 (m, 10H), 1.16 (d, J = 7.0 Hz, 6H), 0.92 – 0.84 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 177.1, 159.2, 129.5, 120.6, 114.6, 73.9, 67.9, 34.4, 34.24, 34.22, 
31.8, 29.4, 29.3, 26.1, 25.4, 25.1, 22.7, 19.3, 14.1. 
FT-IR (film): 2934, 1732, 1601, 1497, 1387, 1245, 751 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C22H40NO3: 366.3003, found: 366.3003. 
[α]23D = +0.5 (c 1.0, CHCl3); 94% ee, from (S,S)-L*. 
 
 
 
9-Phenoxynonan-3-yl pivalate (Figure 3, entry 17).  The title compound was synthesized 
according to GP-4 from 1-bromopropyl pivalate and (hex-5-en-1-yloxy)benzene.  The product 
was purified by column chromatography on silica gel (1:9 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 106 mg, 41% yield, 91% ee; (R,R)-L*: 105 mg, 41% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (0.5% i-
PrOH in hexane, 0.5 mL/min); retention times for compound obtained using (S,S)-L*: 11.7 min 
(major), 13.0 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.17 (m, 2H), 7.03 – 6.82 (m, 3H), 4.89 – 4.72 (m, 1H), 
3.94 (t, J = 6.5 Hz, 2H), 1.83 – 1.72 (m, 2H), 1.63 – 1.49 (m, 4H), 1.49 – 1.28 (m, 6H), 1.20 (s, 9H), 
0.88 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 178.5, 159.2, 129.5, 120.6, 114.6, 75.0, 67.9, 39.0, 33.7, 29.4, 29.3, 
27.4, 27.1, 26.1, 25.3, 9.7. 
FT-IR (film): 2942, 1731, 1601, 1498, 1396, 1244, 754 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C20H36NO3: 338.2690, found: 338.2696. 
[α]23D = +3.1 (c 1.0, CHCl3); 91% ee, from (S,S)-L*. 
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Hexan-3-yl benzoate (Figure 3, entry 18).  In the air, NiBr2⋅diglyme (28.2 mg, 0.081 mmol, 
0.10 equiv), (S,S)-L* (61.2 mg, 0.096 mmol, 0.12 equiv), and K3PO4⋅H2O (552 mg, 2.4 mmol, 3.0 
equiv) were added to an oven-dried 25 mL side-armed Schlenk tube equipped with a stir bar.  
The tube was closed with two rubber septa, and it was placed under a nitrogen atmosphere by 
evacuating and backfilling the tube (three cycles).  Anhydrous MTBE (8.0 mL) was added to 
the tube, and the mixture was stirred at room temperature for 30 min, at which time it was a 
pink heterogeneous solution.  A balloon filled with nitrogen was attached to the side arm.  
Then 1-bromopropyl benzoate (194 mg, 0.80 mmol, 1.0 equiv) and triethoxysilane (440 µL, 2.4 
mmol, 3.0 equiv) were added dropwise in turn to the reaction mixture.  The top rubber 
septum was switched quickly to a Chem-Cap® valve, and the balloon attached to the side arm 
was removed.  The side arm of the Schlenk tube was attached to a vacuum manifold.  The 
solution was frozen in liquid nitrogen, and the tube was placed under vacuum.  The flask 
was sealed under vacuum and separated from the vacuum manifold.  Next, a balloon filled 
with propylene was attached to the side arm.  The gas in the balloon was condensed into the 
Schlenk tube at 77 K (~1.0 mL), and the flask was resealed.  The balloon was removed, and 
the mixture was stirred vigorously (1100 rpm) at room temperature for 20 h. 
Work-up: Same as GP-2.  The product was purified by column chromatography on silica 
gel (1:40 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 139 mg, 84% yield, 89% ee; (R,R)-L*: 130 mg, 79% yield, 87% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.11 – 7.99 (m, 2H), 7.62 – 7.50 (m, 1H), 7.49 – 7.33 (m, 2H), 
5.18 – 5.02 (m, 1H), 1.76 – 1.55 (m, 4H), 1.49 – 1.32 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.2 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.6, 132.8, 131.0, 129.7, 128.4, 76.1, 36.0, 27.3, 18.8, 14.2, 9.8. 
FT-IR (film): 2966, 1717, 1452, 1272, 1107, 712 cm-1. 
GC-MS (EI) m/z [M]+ calcd for C13H18O2: 206.1, found: 206.2. 
[α]23D = −4.8 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
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Hexan-3-yl diphenyl phosphate.  The title compound was synthesized according to GP-5.  
The product was purified by column chromatography on silica gel (1:5 EtOAc/hexanes).  
Colorless oil. 
(S,S)-L*: 33.8 mg, 51% yield, 89% ee; (R,R)-L*: 33.4 mg, 50% yield, 87% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 10.0 min 
(major), 11.9 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.29 (m, 4H), 7.25 – 7.20 (m, 4H), 7.20 – 7.14 (m, 2H), 
4.69 – 4.52 (m, 1H), 1.78 – 1.51 (m, 4H), 1.46 – 1.27 (m, 2H), 0.91 (t, J = 7.6 Hz, 3H), 0.88 (t, J = 7.6 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 7.1 Hz), 129.8, 125.2 (d, J = 1.0 Hz), 120.3 (d, J = 2.0 
Hz), 120.2 (d, J = 2.0 Hz), 83.3 (d, J = 7.1 Hz), 36.6 (d, J = 5.1 Hz), 27.9 (d, J = 4.0 Hz), 18.2, 14.0, 
9.2. 
31P NMR (162 MHz, CDCl3) δ –12.3. 
FT-IR (film): 2964, 2366, 1591, 1489, 1292, 1194, 1016, 772 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C18H27NO4P: 352.1672, found: 352.1680. 
[α]23D = −5.0 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
 
 
 
Heptan-3-yl benzoate (Figure 3, entry 19).  A solution of the catalyst was prepared 
according to GP-2.  After a balloon filled with nitrogen was attached to the reaction vial, 1-
bromopropyl benzoate (194 mg, 0.80 mmol, 1.0 equiv), a solution of 1-butene in toluene (10 
wt.%, 2.24 g, 4.0 mmol, 5.0 equiv), and triethoxysilane (440 µL, 2.4 mmol, 3.0 equiv) were 
added dropwise in turn to the reaction mixture.  The balloon was removed, and the septum 
cap was sealed with vacuum grease.  The mixture was stirred vigorously (1100 rpm) at room 
temperature for 20 h. 
Work-up: Same as GP-2.  The product was purified by column chromatography on silica 
gel (1:40 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 146 mg, 83% yield, 91% ee; (R,R)-L*: 150 mg, 85% yield, 90% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.09 – 8.02 (m, 2H), 7.58 – 7.52 (m, 1H), 7.47 – 7.40 (m, 2H), 
5.08 (tt, J = 7.4, 5.6 Hz, 1H), 1.77 – 1.61 (m, 4H), 1.42 – 1.28 (m, 4H), 0.95 (t, J = 7.5 Hz, 3H), 0.92 – 
0.84 (m, 3H). 
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13C NMR (101 MHz, CDCl3) δ 166.6, 132.8, 131.0, 129.7, 128.4, 76.3, 33.5, 27.7, 27.2, 22.8, 14.2, 
9.8. 
FT-IR (film): 2962, 1716, 1452, 1274, 1110, 711 cm-1. 
GC-MS (EI) m/z [M]+ calcd for C14H20O2: 220.1, found: 220.2. 
[α]23D = −7.2 (c 1.0, CHCl3); 91% ee, from (S,S)-L*. 
 
 
 
Heptan-3-yl diphenyl phosphate.  The title compound was synthesized according to GP-
5.  The product was purified by column chromatography on silica gel (1:5 EtOAc/hexanes).  
Colorless oil. 
(S,S)-L*: 48.4 mg, 70% yield, 91% ee; (R,R)-L*: 49.2 mg, 71% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 9.5 min 
(major), 12.8 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.28 (m, 4H), 7.26 – 7.20 (m, 4H), 7.20 – 7.13 (m, 2H), 
4.71 – 4.45 (m, 1H), 1.74 – 1.55 (m, 4H), 1.37 – 1.19 (m, 4H), 0.91 (t, J = 7.5 Hz, 3H), 0.87 – 0.81 
(m, 3H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 7.1 Hz), 129.8, 125.2, 120.3 (d, J = 2.0 Hz), 120.2 (d, 
J = 1.0 Hz), 83.5 (d, J = 6.1 Hz), 34.2 (d, J = 5.1 Hz), 27.9 (d, J = 4.0 Hz), 27.0, 22.6, 14.0, 9.2. 
31P NMR (162 MHz, CDCl3) δ –12.3. 
FT-IR (film): 2955, 2361, 1593, 1488, 1292, 1199, 1014, 751 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C19H29NO4P: 366.1829, found: 366.1836. 
[α]23D = −3.6 (c 1.0, CHCl3); 91% ee, from (S,S)-L*. 
 
 
 
Nonan-3-yl benzoate (Figure 3, entry 20).  The title compound was synthesized according 
to GP-2 from 1-bromopropyl benzoate and 1-hexene.  The product was purified by column 
chromatography on silica gel (1:40 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 140 mg, 70% yield, 89% ee; (R,R)-L*: 135 mg, 68% yield, 89% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.09 – 8.03 (m, 2H), 7.58 – 7.51 (m, 1H), 7.48 – 7.40 (m, 2H), 
5.18 – 4.99 (m, 1H), 1.77 – 1.62 (m, 4H), 1.44 – 1.19 (m, 8H), 0.95 (t, J = 7.5 Hz, 3H), 0.91 – 0.81 
(m, 3H). 
O
Et
P(OPh)2
O
Et
S–27 
13C NMR (101 MHz, CDCl3) δ 166.6, 132.8, 131.0, 129.7, 128.4, 76.3, 33.8, 31.9, 29.4, 27.2, 25.5, 
22.7, 14.2, 9.8. 
FT-IR (film): 2931, 1716, 1603, 1452, 1272, 1109, 712 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C16H28NO2: 266.2115, found: 266.2117. 
[α]23D = −8.9 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
 
 
 
Nonan-3-yl diphenyl phosphate.  The title compound was synthesized according to GP-
5.  The product was purified by column chromatography on silica gel (1:5 EtOAc/hexanes).  
Colorless oil. 
(S,S)-L*: 56.5 mg, 75% yield, 89% ee; (R,R)-L*: 52.9 mg, 70% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 8.6 min 
(major), 11.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 4H), 7.26 – 7.20 (m, 4H), 7.20 – 7.13 (m, 2H), 
4.68 – 4.50 (m, 1H), 1.76 – 1.54 (m, 4H), 1.38 – 1.14 (m, 8H), 0.91 (t, J = 7.4 Hz, 3H), 0.86 (t, J = 6.9 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 7.1 Hz), 129.8, 125.2 (d, J = 1.0 Hz), 120.2 (d, J = 5.1 
Hz), 83.5 (d, J = 6.1 Hz), 34.5 (d, J = 5.1 Hz), 31.8, 29.2, 27.9 (d, J = 4.0 Hz), 24.8, 22.6, 14.2, 9.2. 
31P NMR (162 MHz, CDCl3) δ –12.3. 
FT-IR (film): 2936, 1594, 1495, 1294, 1202, 1012, 764 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C21H33NO4P: 394.2142, found: 394.2147. 
[α]23D = −3.3 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
 
 
 
7-Methyloctan-3-yl benzoate (Figure 3, entry 21).  The title compound was synthesized 
according to GP-2 from 1-bromopropyl benzoate and 4-methylpent-1-ene.  The product was 
purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 158 mg, 80% yield, 90% ee; (R,R)-L*: 149 mg, 75% yield, 91% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.09 – 8.03 (m, 2H), 7.59 – 7.52 (m, 1H), 7.48 – 7.41 (m, 2H), 
5.16 – 5.01 (m, 1H), 1.76 – 1.58 (m, 4H), 1.58 – 1.46 (m, 1H), 1.44 – 1.29 (m, 2H), 1.26 – 1.13 (m, 
2H), 0.95 (t, J = 7.5 Hz, 3H), 0.85 (d, J = 6.6 Hz, 6H). 
O
Et
P(OPh)2
O
n-Bu
S–28 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.8, 131.0, 129.7, 128.4, 76.3, 39.0, 34.0, 27.9, 27.2, 23.3, 
22.72, 22.65, 9.8. 
FT-IR (film): 2953, 1716, 1603, 1453, 1274, 1111, 711 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C16H24NaO2: 271.1669, found: 271.1673. 
[α]23D = −10.6 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 
 
 
7-Methyloctan-3-yl diphenyl phosphate.  The title compound was synthesized according 
to GP-5.  The product was purified by column chromatography on silica gel (1:5 
EtOAc/hexanes).  Colorless oil. 
(S,S)-L*: 44.4 mg, 59% yield, 90% ee; (R,R)-L*: 45.9 mg, 61% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 9.0 min 
(major), 12.2 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 4H), 7.26 – 7.20 (m, 4H), 7.20 – 7.14 (m, 2H), 
4.67 – 4.53 (m, 1H), 1.77 – 1.52 (m, 4H), 1.51 – 1.40 (m, 1H), 1.39 – 1.20 (m, 2H), 1.19 – 1.04 (m, 
2H), 0.91 (t, J = 7.4 Hz, 3H), 0.83 (d, J = 6.6 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 8.1 Hz), 129.8, 125.2 (d, J = 1.0 Hz), 120.23 (d, J = 
2.0 Hz), 120.19 (d, J = 2.0 Hz), 83.5 (d, J = 7.1 Hz), 38.8, 34.7 (d, J = 5.1 Hz), 28.0, 27.94, 27.91, 22.7, 
22.6 (d, J = 2.0 Hz), 9.2. 
31P NMR (162 MHz, CDCl3) δ –12.3. 
FT-IR (film): 2956, 1593, 1488, 1290, 1199, 1012, 764 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C21H33NO4P: 394.2142, found: 394.2143. 
[α]23D = −3.5 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 
 
 
6-Cyclopentylhexan-3-yl benzoate (Figure 3, entry 22).  The title compound was 
synthesized according to GP-2 from 1-bromopropyl benzoate and allylcyclopentane.  The 
product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L*: 159 mg, 72% yield, 88% ee; (R,R)-L*: 165 mg, 75% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (0.5% i-
PrOH in hexane, 0.5 mL/min); retention times for compound obtained using (S,S)-L*: 11.0 min 
(major), 11.9 min (minor). 
O
Et
P(OPh)2
O
i-Bu
S–29 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.00 (m, 2H), 7.58 – 7.52 (m, 1H), 7.47 – 7.40 (m, 2H), 
5.19 – 5.00 (m, 1H), 1.76 – 1.27 (m, 15H), 1.12 – 0.98 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.6, 132.8, 131.0, 129.7, 128.4, 76.3, 40.1, 36.2, 34.1, 32.81, 
32.76, 27.2, 25.3, 24.7, 9.8. 
FT-IR (film): 2948, 1716, 1451, 1270, 1110, 710 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C18H30NO2: 292.2271, found: 292.2274. 
[α]23D = −10.6 (c 1.0, CHCl3); 88% ee, from (S,S)-L*. 
The title compound was also synthesized according to GP-2, using 2.0 equiv of the olefin: 
(S,S)-L*: 160 mg, 73% yield, 89% ee; (R,R)-L*: 158 mg, 72% yield, 90% ee. 
 
 
 
6-Cyclohexylhexan-3-yl benzoate (Figure 3, entry 23).  The title compound was 
synthesized according to GP-2 from 1-bromopropyl benzoate and allylcyclohexane.  The 
product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L*: 174 mg, 76% yield, 90% ee; (R,R)-L*: 176 mg, 76% yield, 90% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate. 
1H NMR (400 MHz, CDCl3) δ 8.10 – 8.02 (m, 2H), 7.59 – 7.52 (m, 1H), 7.49 – 7.40 (m, 2H), 
5.17 – 4.99 (m, 1H), 1.77 – 1.54 (m, 9H), 1.46 – 1.28 (m, 2H), 1.27 – 1.05 (m, 6H), 0.95 (t, J = 7.5 
Hz, 3H), 0.90 – 0.75 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.6, 132.8, 131.0, 129.7, 128.4, 76.4, 37.6, 37.5, 34.1, 33.5, 33.4, 
27.2, 26.8, 26.53, 26.52, 22.8, 9.8. 
FT-IR (film): 2926, 1716, 1451, 1273, 1116, 712 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C19H32NO2: 306.2428, found: 306.2431. 
[α]23D = −12.1 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 
 
 
6-Cyclohexylhexan-3-yl diphenyl phosphate.  The title compound was synthesized 
according to GP-5.  The product was purified by column chromatography on silica gel (1:5 
EtOAc/hexanes).  Colorless oil. 
(S,S)-L*: 81.4 mg, 98% yield, 90% ee; (R,R)-L*: 81.5 mg, 98% yield, 90% ee. 
O
Et
P(OPh)2
O
Cy
S–30 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 8.6 min 
(major), 10.2 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.28 (m, 4H), 7.27 – 7.20 (m, 4H), 7.20 – 7.10 (m, 2H), 
4.68 – 4.50 (m, 1H), 1.75 – 1.50 (m, 9H), 1.40 – 1.02 (m, 8H), 0.91 (t, J = 7.5 Hz, 3H), 0.87 – 0.70 
(m, 2H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 7.1 Hz), 129.7, 125.2, 120.2 (d, J = 5.1 Hz), 83.5 (d, J 
= 6.1 Hz), 37.6, 37.3, 34.7 (d, J = 5.1 Hz), 33.38, 33.35, 28.0, 27.9, 26.8, 26.5, 22.2, 9.2. 
31P NMR (162 MHz, CDCl3) δ –12.3. 
FT-IR (film): 2920, 1596, 1488, 1286, 1195, 1022, 756 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C24H37NO4P: 434.2455, found: 434.2458. 
[α]23D = −3.9 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 
 
 
7,7-Dimethyloctan-3-yl benzoate (Figure 3, entry 24).  The title compound was 
synthesized according to GP-2 from 1-bromopropyl benzoate and 4,4-dimethylpent-1-ene.  
The product was purified by column chromatography on silica gel (1:40 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 165 mg, 79% yield, 88% ee; (R,R)-L*: 162 mg, 77% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (0.5% i-
PrOH in hexane, 0.5 mL/min); retention times for compound obtained using (S,S)-L*: 10.3 min 
(minor), 11.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 8.11 – 7.99 (m, 2H), 7.60 – 7.51 (m, 1H), 7.50 – 7.38 (m, 2H), 
5.16 – 5.02 (m, 1H), 1.78 – 1.53 (m, 4H), 1.42 – 1.12 (m, 4H), 0.95 (t, J = 7.4 Hz, 3H), 0.84 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 166.6, 132.8, 131.0, 129.7, 128.4, 76.3, 44.2, 34.7, 30.4, 29.5, 27.2, 
20.5, 9.8. 
FT-IR (film): 2948, 1716, 1452, 1272, 1113, 711 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C17H30NO2: 280.2271, found: 280.2267. 
[α]23D = −10.8 (c 1.0, CHCl3); 88% ee, from (S,S)-L*. 
 
 
 
9-Methoxy-9-oxononan-3-yl benzoate (Figure 3, entry 25).  The title compound was 
synthesized according to GP-2 from 1-bromopropyl benzoate and methyl hex-5-enoate.  The 
S–31 
product was purified by column chromatography on silica gel (1:4 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L*: 146 mg, 62% yield, 86% ee; (R,R)-L*: 148 mg, 63% yield, 88% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (1% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 8.6 min 
(major), 9.3 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.13 – 7.99 (m, 2H), 7.63 – 7.50 (m, 1H), 7.49 – 7.35 (m, 2H), 
5.15 – 5.00 (m, 1H), 3.64 (s, 3H), 2.29 (t, J = 7.5 Hz, 2H), 1.75 – 1.55 (m, 6H), 1.46 – 1.29 (m, 4H), 
0.94 (t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 174.3, 166.5, 132.9, 130.9, 129.7, 128.4, 76.1, 51.6, 34.1, 33.6, 
29.2, 27.2, 25.2, 24.9, 9.8. 
FT-IR (film): 2940, 1715, 1456, 1274, 1112, 715 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C17H28NO4: 310.2013, found: 310.2016. 
[α]23D = −8.7 (c 1.0, CHCl3); 86% ee, from (S,S)-L*. 
 
 
 
7-Phenoxyheptan-3-yl benzoate (Figure 3, entry 26).  The title compound was 
synthesized according to GP-2 from 1-bromopropyl benzoate and (but-3-en-1-yloxy)benzene.  
The product was purified by column chromatography on silica gel (1:10 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 171 mg, 69% yield, 89% ee; (R,R)-L*: 179 mg, 72% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (1% i-
PrOH in hexane, 0.5 mL/min); retention times for compound obtained using (S,S)-L*: 7.0 min 
(major), 7.8 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.16 – 8.01 (m, 2H), 7.60 – 7.53 (m, 1H), 7.49 – 7.42 (m, 2H), 
7.31 – 7.23 (m, 2H), 6.97 – 6.90 (m, 1H), 6.89 – 6.83 (m, 2H), 5.20 – 5.06 (m, 1H), 3.95 (t, J = 6.4 
Hz, 2H), 1.93 – 1.67 (m, 6H), 1.66 – 1.47 (m, 2H), 0.97 (t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 159.1, 132.9, 130.9, 129.7, 129.5, 128.5, 120.6, 114.6, 76.0, 
67.6, 33.6, 29.3, 27.2, 22.1, 9.8. 
FT-IR (film): 2948, 1715, 1601, 1495, 1272, 1110, 710 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C20H24NaO3: 335.1618, found: 335.1621. 
[α]23D = −11.5 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
The title compound was also synthesized according to GP-2, using 2.0 equiv of the olefin: 
(S,S)-L*: 159 mg, 64% yield, 89% ee; (R,R)-L*: 163 mg, 65% yield, 90% ee. 
 
 
S–32 
 
9-Bromononan-3-yl benzoate (Figure 3, entry 27).  The title compound was synthesized 
according to GP-2 from 1-bromopropyl benzoate and 6-bromohex-1-ene.  The product was 
purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 165 mg, 63% yield, 92% ee; (R,R)-L*: 171 mg, 66% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (0.5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 8.2 min 
(major), 9.5 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.12 – 7.99 (m, 2H), 7.62 – 7.50 (m, 1H), 7.50 – 7.38 (m, 2H), 
5.14 – 5.01 (m, 1H), 3.38 (t, J = 6.8 Hz, 2H), 1.89 – 1.79 (m, 2H), 1.75 – 1.62 (m, 4H), 1.48 – 1.30 
(m, 6H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.9, 130.9, 129.7, 128.5, 76.1, 34.1, 33.7, 32.8, 28.8, 28.2, 
27.2, 25.3, 9.8. 
FT-IR (film): 2933, 2358, 1714, 1602, 1451, 1277, 1112, 710 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C16H27BrNO2: 344.1220, found: 344.1227. 
[α]23D = −8.0 (c 1.0, CHCl3); 92% ee, from (S,S)-L*. 
 
 
 
9-Chlorononan-3-yl benzoate (Figure 3, entry 28).  The title compound was synthesized 
according to GP-2 from 1-bromopropyl benzoate and 6-chlorohex-1-ene.  The product was 
purified by column chromatography on silica gel (1:40 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 157 mg, 70% yield, 88% ee; (R,R)-L*: 147 mg, 65% yield, 87% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (1% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 5.8 min 
(major), 6.4 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.13 – 8.00 (m, 2H), 7.62 – 7.51 (m, 1H), 7.50 – 7.38 (m, 2H), 
5.16 – 5.01 (m, 1H), 3.51 (t, J = 6.7 Hz, 2H), 1.80 – 1.62 (m, 6H), 1.48 – 1.30 (m, 6H), 0.95 (t, J = 7.5 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.6, 132.9, 130.9, 129.7, 128.5, 76.2, 45.2, 33.7, 32.7, 28.9, 27.3, 
26.9, 25.4, 9.8. 
FT-IR (film): 2934, 2358, 1715, 1602, 1452, 1276, 1114, 717 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C16H27ClNO2: 300.1725, found: 300.1729. 
[α]23D = −9.2 (c 1.0, CHCl3); 88% ee, from (S,S)-L*. 
 
 
S–33 
 
8-(1,3-Dioxan-2-yl)octan-3-yl benzoate (Figure 3, entry 29).  The title compound was 
synthesized according to GP-2 from 1-bromopropyl benzoate and 2-(pent-4-en-1-yl)-1,3-
dioxane.  The product was purified by column chromatography on silica gel (1:4 
Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 173 mg, 68% yield, 89% ee; (R,R)-L*: 176 mg, 69% yield, 88% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (1% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 9.2 min 
(minor), 10.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 8.12 – 8.00 (m, 2H), 7.61 – 7.50 (m, 1H), 7.48 – 7.35 (m, 2H), 
5.14 – 5.00 (m, 1H), 4.48 (t, J = 5.2 Hz, 1H), 4.14 – 4.02 (m, 2H), 3.78 – 3.65 (m, 2H), 2.16 – 1.96 
(m, 1H), 1.77 – 1.51 (m, 6H), 1.46 – 1.27 (m, 7H), 0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.8, 131.0, 129.7, 128.4, 102.4, 76.2, 67.0, 35.3, 33.7, 
29.5, 27.2, 26.0, 25.4, 24.0, 9.8. 
FT-IR (film): 2951, 1716, 1456, 1276, 1145, 714 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C19H32NO4: 338.2326, found: 338.2335. 
[α]23D = −8.3 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
 
 
 
8-(((8R,9S,13S,14S)-13-Methyl-6,7,8,9,11,12,13,14,15,16 
decahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-yl)oxy)octan-3-yl 
benzoate (Figure 3, entries 30 and 31).  The title compound was synthesized according to 
GP-2 from 1-bromopropyl benzoate and (8R,9S,13S,14S)-13-methyl-3-(pent-4-en-1-yloxy)-
6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolane].  
The product was purified by column chromatography on silica gel (1:4 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 354 mg, 81% yield, 95:5 d.r.; (R,R)-L*: 344 mg, 79% yield, 7:93 d.r. 
HPLC analysis: The d.r. was determined via HPLC on a CHIRALPAK IC column (5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 10.0 min 
(major), 10.9 min (minor). 
S–34 
NMR data for the product from (S,S)-L*: 
1H NMR (400 MHz, CDCl3) δ 8.12 – 7.99 (m, 2H), 7.63 – 7.51 (m, 1H), 7.48 – 7.40 (m, 2H), 
7.18 (d, J = 8.7 Hz, 1H), 6.67 (dd, J = 8.6, 2.8 Hz, 1H), 6.60 (d, J = 2.7 Hz, 1H), 5.16 – 5.02 (m, 1H), 
3.99 – 3.87 (m, 6H), 2.88 – 2.77 (m, 2H), 2.38 – 2.16 (m, 2H), 2.10 – 1.97 (m, 1H), 1.92 – 1.59 (m, 
11H), 1.57 – 1.28 (m, 9H), 0.96 (t, J = 7.4 Hz, 3H), 0.88 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 157.0, 138.1, 132.8, 132.7, 130.9, 129.7, 128.4, 126.4, 119.6, 
114.5, 112.1, 76.2, 67.8, 65.4, 64.7, 49.5, 46.3, 43.8, 39.2, 34.4, 33.8, 30.9, 29.9, 29.4, 27.2, 27.1, 26.3, 
26.2, 25.3, 22.5, 14.5, 9.8. 
NMR data for the product from (R,R)-L*: 
1H NMR (400 MHz, CDCl3) δ 8.13 – 7.99 (m, 2H), 7.59 – 7.52 (m, 1H), 7.48 – 7.41 (m, 2H), 
7.18 (d, J = 8.6 Hz, 1H), 6.67 (dd, J = 8.6, 2.8 Hz, 1H), 6.60 (d, J = 2.7 Hz, 1H), 5.16 – 5.02 (m, 1H), 
4.02 – 3.87 (m, 6H), 2.87 – 2.78 (m, 2H), 2.37 – 2.17 (m, 2H), 2.10 – 1.98 (m, 1H), 1.92 – 1.61 (m, 
11H), 1.57 – 1.28 (m, 9H), 0.95 (t, J = 7.4 Hz, 3H), 0.88 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.6, 157.0, 138.1, 132.9, 132.7, 130.9, 129.7, 128.4, 126.4, 119.6, 
114.6, 112.1, 76.2, 67.8, 65.4, 64.7, 49.5, 46.3, 43.8, 39.2, 34.4, 33.8, 30.9, 29.9, 29.4, 27.2, 27.1, 26.3, 
26.2, 25.3, 22.5, 14.5, 9.8. 
FT-IR (film): 3416, 2922, 1714, 1607, 1470, 1275, 717 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C35H50NO5: 564.3684, found: 564.3679. 
[α]23D = +13.5 (c 1.0, CHCl3); 95:5 d.r., from (S,S)-L*. 
[α]23D = +22.4 (c 1.0, CHCl3); 7:93 d.r., from (R,R)-L*. 
The title compound was also synthesized according to GP-2, using 2.0 equiv of the olefin: 
(S,S)-L*: 281 mg, 64% yield, 94:6 d.r.; (R,R)-L*: 294 mg, 67% yield, 6:94 d.r. 
 
 
 
9-((Ethoxycarbonyl)oxy)nonan-3-yl benzoate (Figure 3, entry 32).  The title compound 
was synthesized according to GP-2 from 1-bromopropyl benzoate and ethyl hex-5-en-1-yl 
carbonate.  The product was purified by column chromatography on silica gel (1:5 
Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 169 mg, 63% yield, 91% ee; (R,R)-L*: 175 mg, 65% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (1% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 8.8 min 
(major), 9.9 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.14 – 7.99 (m, 2H), 7.61 – 7.50 (m, 1H), 7.49 – 7.37 (m, 2H), 
5.14 – 5.00 (m, 1H), 4.18 (q, J = 7.1 Hz, 2H), 4.10 (t, J = 6.7 Hz, 2H), 1.77 – 1.57 (m, 6H), 1.44 – 1.22 
(m, 9H), 0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 155.4, 132.9, 130.9, 129.7, 128.4, 76.2, 68.0, 63.9, 33.7, 
29.3, 28.7, 27.2, 25.8, 25.4, 14.4, 9.8. 
S–35 
FT-IR (film): 2939, 2357, 1716, 1603, 1455, 1269, 1109, 712 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C19H28NaO5: 359.1829, found: 359.1838. 
[α]23D = −8.1 (c 1.0, CHCl3); 91% ee, from (S,S)-L*. 
 
 
 
8-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)octan-3-yl benzoate (Figure 3, entry 33).  
The title compound was synthesized according to GP-2 from 1-bromopropyl benzoate and 
4,4,5,5-tetramethyl-2-(pent-4-en-1-yl)-1,3,2-dioxaborolane.  The product was purified by 
column chromatography on silica gel (1:4 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 194 mg, 68% yield, 88% ee; (R,R)-L*: 182 mg, 63% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 20.1 min 
(minor), 21.4 min (major). 
1H NMR (400 MHz, CDCl3) δ 8.13 – 7.99 (m, 2H), 7.58 – 7.51 (m, 1H), 7.47 – 7.39 (m, 2H), 
5.16 – 4.98 (m, 1H), 1.74 – 1.61 (m, 4H), 1.45 – 1.26 (m, 6H), 1.23 (s, 12H), 0.94 (t, J = 7.5 Hz, 3H), 
0.75 (t, J = 7.6 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 132.8, 131.0, 129.7, 128.4, 83.0, 76.3, 33.7, 32.5, 27.2, 25.3, 
24.9, 24.0, 11.4, 9.8. 
FT-IR (film): 2933, 1716, 1456, 1361, 1113, 717 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C21H37BNO4: 378.2810, found: 378.2817. 
[α]23D = −8.5 (c 1.0, CHCl3); 88% ee, from (S,S)-L*. 
 
 
 
8-(1,3-Dioxoisoindolin-2-yl)octan-3-yl benzoate (Figure 3, entry 34).  The title compound 
was synthesized according to GP-2 from 1-bromopropyl benzoate and 2-(pent-4-en-1-
yl)isoindoline-1,3-dione.  The product was purified by column chromatography on silica gel 
(1:3 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 223 mg, 74% yield, 89% ee; (R,R)-L*: 234 mg, 77% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (10% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 13.4 min 
(major), 16.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.11 – 7.99 (m, 2H), 7.90 – 7.79 (m, 2H), 7.77 – 7.64 (m, 2H), 
7.60 – 7.49 (m, 1H), 7.49 – 7.36 (m, 2H), 5.13 – 4.98 (m, 1H), 3.66 (t, J = 7.6 Hz, 2H), 1.79 – 1.55 
(m, 6H), 1.50 – 1.27 (m, 4H), 0.93 (t, J = 7.4 Hz, 3H). 
S–36 
13C NMR (101 MHz, CDCl3) δ 168.6, 166.5, 134.0, 132.8, 132.3, 130.9, 129.7, 128.4, 123.3, 76.1, 
38.1, 33.7, 28.6, 27.2, 27.0, 25.1, 9.8. 
FT-IR (film): 3470, 2922, 1714, 1277, 701 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C23H25NNaO4: 402.1676, found: 402.1677. 
[α]23D = −4.4 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
The title compound was also synthesized according to GP-2, using 2.0 equiv of the olefin: 
(S,S)-L*: 202 mg, 67% yield, 89% ee; (R,R)-L*: 205 mg, 68% yield, 89% ee. 
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 IV.  Effect of Reaction Parameters 
 
General Procedure 6 (GP-6). 
Preparation of a solution of the catalyst: In a nitrogen-filled glovebox, an oven-dried 4 mL 
vial that contained a magnetic stir bar was charged with NiBr2⋅diglyme (3.5 mg, 0.010 mmol, 
0.10 equiv), (S,S)-L* (7.7 mg, 0.012 mmol, 0.12 equiv), and K3PO4⋅H2O (69 mg, 0.30 mmol, 3.0 
equiv).  Next, anhydrous MTBE (1.0 mL) was added, the vial was capped with a PTFE 
septum cap, and the mixture was stirred at room temperature for 30 min, at which time it was 
a pink heterogeneous solution. 
Coupling: In a nitrogen-filled glovebox, the electrophile (0.10 mmol, 1.0 equiv), olefin (0.30 
mmol, 3.0 equiv), and triethoxysilane (55 µL, 0.30 mmol, 3.0 equiv) were added in turn 
dropwise to the reaction mixture.  The vial was capped with a PTFE septum cap and taken 
out of the glovebox.  The mixture was stirred vigorously (1100 rpm) at room temperature for 
20 h. 
Work-up: n-Dodecane (23 µL, 0.10 mmol, 1.0 equiv) was added via syringe.  The reaction 
mixture was passed through a short pad of silica gel, with Et2O as the eluent.  The solvent 
was removed under reduced pressure, and the residue was purified by chromatography. 
 
1-Bromopropyl benzoate was reacted with vinylcyclohexane according to GP-6.  The 
yields were determined via GC analysis, with n-dodecane as the internal standard.  The ee 
values were determined via HPLC analysis after purification by preparative thin-layer 
chromatography.  All data are the average of two experiments. 
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Table S-1.  Effect of Reaction Parameters. 
 
  
racemic
10 mol% NiBr2 • diglyme
12 mol% (S,S)–L*
"standard conditions”
O
EtBr
3.0 equiv
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
none
no NiBr2 • diglyme
no (S,S)–L*
L1, instead of (S,S)–L*
L2, instead of (S,S)–L*
L3, instead of (S,S)–L*
L4, instead of (S,S)–L*
L5, instead of (S,S)–L*
i-Pr2O, instead of MTBE
Et2O, instead of MTBE
5.0 mol% NiBr2 • diglyme, 6.0 mol% (S,S)–L*
2.0 equiv vinylcyclohexane
1.5 equiv (EtO)3SiH, 1.5 equiv K3PO4• H2O
(MeO)3SiH, instead of (EtO)3SiH
(EtO)2MeSiH, instead of (EtO)3SiH
10, instead of 20, h
0.1 equiv H2O added
under air in a closed vial
92
–
–
19
<2
<2
51
<2
92
90
85
89
92
92
89
91
92
90
All data are the average of two experiments.  a Determined through GC 
analysis.  b Determined through HPLC analysis.
78
<1
<1
31
8
15
7
10
74
64
38
59
53
74
63
59
76
61
L1
N
N
OO
N
PhPh L4
N
OO
N PhPh
L2
N N
O
Ph
NHMe
PhPh
MeHN
L3 L5
(S,S)–L*
Cy
Ph
O
O
Et
Ph
O
Cy
N
OO
N
PhPh
MeMe
Ph
Ph
Ph
Ph
3.0 equiv (EtO)3SiH
3.0 equiv K3PO4 • H2O
MTBE, r.t., 20 h
N
OO
N
PhPh
MeMe
variation from the “standard conditions” yield (%) a ee (%) bentry
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V.  Functional-Group Compatibility 
 
1-Bromopropyl benzoate was reacted with vinylcyclohexane according to GP-6, in the 
presence of 1.0 equiv of the additives shown below.  The additive was added after the 
vinylcyclohexane. 
The yield of the coupling product and the percent recovery of the additive were 
determined via GC analysis, with n-dodecane as the internal standard.  The ee values were 
determined via HPLC analysis after purification by preparative thin-layer chromatography. 
 
Table S-2.  Functional-Group Compatibility. 
 
 
without additive:
78% yield, 92% ee
entry
1
2
3
4
5
6
7
8
9
10
11
12
additive ee (%) b
91
91
91
89
89
89
90
90
91
87
90
91
a Analyzed via GC.
b Analyzed via HPLC.
yield (%) a
80
78
81
79
76
80
79
78
78
79
76
81
Br
I
Cl
Br
I
OTs
SPh
SEt
O
S
recovery of additive (%)
>95
>95
>95
>95
>95
>95
>95
>95
>95
>95
>95
>95
entry
13
14
15
16
17
18
19
20
21
22
23
24
additive ee (%) b
91
90
89
91
91
89
89
84
90
92
52
66
yield (%) a
79
77
78
78
65
72
66
54
76
43
18
20
recovery of additive (%)
>95
>95
>95
>95
>95
>95
>95
>95
64
94
88
59
Me
N
NPh
H
N
n-Bu
Cy
N
Cy
Et
n-Oct H
O
CHO
Me
C9H19 Me
O
Ph Me
O
Ph NMe2
O
O
n-Bu n-Bu
Cy
OH
Me
OTf
Me
CN
Me
Me
racemic
10 mol% NiBr2 • diglyme
12 mol% (S,S)–L*
O
EtBr
3.0 equiv
Cy
Ph
O
O
Et
Ph
O
Cy
3.0 equiv (EtO)3SiH
3.0 equiv K3PO4 • H2O
MTBE, r.t., 20 h
additive (1 equiv)
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VI.  Four-Component Reactions 
 
General Procedure 7 (GP-7): MTBE as the solvent. 
Preparation of a solution of the electrophile: In the air, ZnF2 (8.2 mg, 0.080 mmol, 0.10 
equiv) was added to an oven-dried 4 mL vial equipped with a stir bar.  The vial was closed 
with a PTFE septum cap, the joint was wrapped with electrical tape, and the vial was placed 
under a nitrogen atmosphere by evacuating and backfilling the vial (three cycles).  Then, the 
acyl bromide (0.80 mmol, 1.0 equiv) and DCM (0.5 mL) were added.  The resulting solution 
was cooled to –20 °C, and the resulting mixture was stirred for 10 min.  At this temperature, 
the aldehyde (1.0 equiv) was added dropwise via microsyringe over 1 min, and the resulting 
mixture was stirred for 2 h. 
Preparation of a solution of the catalyst: In the air, NiBr2⋅diglyme (28.2 mg, 0.081 mmol, 
0.10 equiv), (S,S)-L* (61.2 mg, 0.096 mmol, 0.12 equiv), and K3PO4⋅H2O (552 mg, 2.4 mmol, 3.0 
equiv) were added to a separate oven-dried 40 mL vial equipped with a cross stir bar.  The 
vial was closed with a PTFE septum cap, the joint was wrapped with electrical tape, and the 
vial was placed under a nitrogen atmosphere by evacuating and backfilling the vial (three 
cycles).  Anhydrous MTBE (4 mL) was added to the vial, and the mixture was stirred at room 
temperature for 30 min. 
Coupling: A balloon filled with nitrogen was attached to a 40 mL vial.  Then, the solution 
of the electrophile was added via syringe in one portion.  The 4 mL vial was rinsed with 
MTBE, and the rinses (2 mL x 2) were added to the 40 mL vial.  Next, the olefin (2.4 mmol, 3.0 
equiv) and triethoxysilane (440 µL, 2.4 mmol, 3.0 equiv) were added in turn dropwise to the 
reaction mixture.  The balloon was removed, and the septum cap was sealed with vacuum 
grease.  The mixture was stirred vigorously (1100 rpm) at room temperature for 20 h. 
Work-up: The reaction mixture was passed through a plug of silica gel, and the vial, the 
cap, and the silica gel were rinsed with Et2O.  The filtrate was concentrated, and the residue 
was purified by flash chromatography on silica gel. 
 
General Procedure 8 (GP-8): i-Pr2O as the solvent. 
Preparation of the electrophile: Same as GP-7. 
Preparation of a solution of the catalyst: In the air, NiBr2⋅diglyme (28.2 mg, 0.081 mmol, 
0.10 equiv), (S,S)-L* (61.2 mg, 0.096 mmol, 0.12 equiv), and K3PO4⋅H2O (368 mg, 1.6 mmol, 2.0 
equiv) were added to a separate oven-dried 40 mL vial equipped with a cross stir bar.  The 
vial was closed with a PTFE septum cap, the joint was wrapped with electrical tape, and the 
vial was placed under a nitrogen atmosphere by evacuating and backfilling the vial (three 
cycles).  Anhydrous i-Pr2O (2 mL) was added to the vial, and the mixture was stirred at room 
temperature for 30 min. 
Coupling: A balloon filled with nitrogen was attached to a 40 mL vial.  Then, the solution 
of the electrophile was added via syringe in one portion.  The 4 mL vial was rinsed with i-
Pr2O, and the rinses (1 mL x 2) were added to the 40 mL vial.  Next, the olefin (2.4 mmol, 3.0 
S–41 
equiv) and triethoxysilane (300 µL, 1.6 mmol, 2.0 equiv) were added in turn dropwise to the 
reaction mixture.  The balloon was removed, and the septum cap was sealed with vacuum 
grease.  The mixture was stirred vigorously (1100 rpm) at room temperature for 20 h. 
Work-up: Same as GP-7. 
 
 
 
1-Cyclohexylpentan-3-yl benzoate (Figure 4, entry 35).  The title compound was 
synthesized according to GP-7 from benzoyl bromide, propionaldehyde, and 
vinylcyclohexane.  The product was purified by column chromatography on silica gel (1:40 
Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 151 mg, 69% yield, 92% ee; (R,R)-L*: 158 mg, 72% yield, 90% ee. 
 
 
 
1-Cyclobutyl-3-cyclohexylpropyl benzoate (Figure 4, entry 36).  The title compound was 
synthesized according to GP-7 from benzoyl bromide, cyclobutanecarbaldehyde, and 
vinylcyclohexane.  The product was purified by column chromatography on silica gel (1:40 
Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 170 mg, 71% yield, 95% ee; (R,R)-L*: 169 mg, 70% yield, 96% ee. 
 
 
 
12-Phenoxydodecan-6-yl acetate (Figure 4, entry 37).  The title compound was 
synthesized according to GP-8 from acetyl bromide, hexanal, and (hex-5-en-1-yloxy)benzene.  
The product was purified by column chromatography on silica gel (1:9 Et2O/hexanes).  
Colorless oil. 
(S,S)-L*: 150 mg, 58% yield, 91% ee; (R,R)-L*: 149 mg, 58% yield, 91% ee. 
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1-Chloro-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)decan-5-yl (1r,4r)-4-
methylcyclohexane-1-carboxylate (Figure 4, entry 38).  The title compound was synthesized 
according to GP-8 from (1r,4r)-4-methylcyclohexane-1-carbonyl bromide, 5-chloropentanal, 
and 4,4,5,5-tetramethyl-2-(pent-4-en-1-yl)-1,3,2-dioxaborolane.  The product was purified by 
column chromatography on silica gel (1:5 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 234 mg, 66% yield, 92% ee; (R,R)-L*: 229 mg, 65% yield, 92% ee. 
HPLC analysis: The ee was determined after transforming the Bpin group to an OBz group 
(see below). 
1H NMR (400 MHz, CDCl3) δ 4.92 – 4.78 (m, 1H), 3.51 (t, J = 6.8 Hz, 2H), 2.17 (tt, J = 12.2, 3.6 
Hz, 1H), 1.97 – 1.88 (m, 2H), 1.83 – 1.68 (m, 4H), 1.58 – 1.17 (m, 27H), 0.98 – 0.90 (m, 2H), 0.88 
(d, J = 6.4 Hz, 3H), 0.75 (t, 2H). 
13C NMR (101 MHz, CDCl3) δ 176.2, 94.1, 83.0, 73.3, 45.0, 43.7, 34.4, 34.2, 33.5, 32.5, 32.4, 32.2, 
29.3, 25.2, 25.0, 24.0, 22.71, 22.67, 11.6. 
FT-IR (film): 3420, 2918, 1734, 1448, 1267, 1146, 850, 728 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C24H48BClNO4: 460.3359, found: 460.3352. 
[α]23D = −3.7 (c 1.0, CHCl3); 92% ee, from (S,S)-L*. 
 
 
 
10-Chloro-6-(((1r,4r)-4-methylcyclohexane-1-carbonyl)oxy)decyl benzoate.  The purified 
product (44.2 mg, 0.10 mmol, 1.0 equiv) was oxidized with NaBO3·4H2O (73.8 mg, 0.48 mmol, 
4.8 equiv) in THF/H2O (1:1; 6 mL) at room temperature for 16 h.  The mixture was extracted 
with Et2O (5 mL x 3).  The combined organic layers were dried over Na2SO4, filtered, and 
concentrated to afford the primary alcohol, which was used without further purification. 
In the air, benzoyl chloride (24 uL, 0.21 mmol, 2.0 equiv) was added to a solution of the 
primary alcohol and pyridine (16 uL, 0.20 mmol, 2.0 equiv) in DCM (2 mL).  The reaction 
mixture was stirred at room temperature for 3 h, and then it was concentrated.  The product 
was purified by flash chromatography on silica gel (1:5 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 33.1 mg, 76% yield, 92% ee; (R,R)-L*: 29.8 mg, 68% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (3% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 7.5 min 
(major), 8.9 min (minor). 
1H NMR (400 MHz, CDCl3) 8.09 – 7.98 (m, 2H), 7.62 – 7.50 (m, 1H), 7.49 – 7.37 (m, 2H), 4.97 
– 4.79 (m, 1H), 4.30 (t, J = 6.6 Hz, 2H), 3.51 (t, J = 6.6 Hz, 2H), 2.18 (tt, J = 12.2, 3.5 Hz, 1H), 2.01 – 
S–43 
1.86 (m, 2H), 1.85 – 1.67 (m, 6H), 1.63 – 1.27 (m, 13H), 0.97 – 0.90 (m, 2H), 0.88 (d, J = 6.8 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ 176.3, 166.8, 133.0, 130.6, 129.7, 128.5, 73.1, 65.0, 45.0, 43.6, 
34.4, 34.2, 33.5, 32.4, 32.1, 29.3, 28.8, 26.1, 25.1, 22.71, 22.65. 
FT-IR (film): 3441, 2938, 2332, 1716, 1452, 1267, 1166, 1026, 718 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C25H37ClNaO4: 459.2273, found: 459.2285. 
[α]23D = −2.1 (c 0.35, CHCl3); 92% ee, from (S,S)-L*. 
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VII.  Applications 
 
 
9-Acetoxynonan-3-yl benzoate (Figure 4, entry 39).  The title compound was synthesized 
according to GP-7 from benzoyl bromide, propionaldehyde, and hex-5-en-1-yl acetate.  The 
product was purified by column chromatography on silica gel (1:5 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L*: 136 mg, 55% yield, 90% ee; (R,R)-L*: 133 mg, 54% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 6.9 min 
(major), 7.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.15 – 7.97 (m, 2H), 7.64 – 7.49 (m, 1H), 7.50 – 7.38 (m, 2H), 
5.15 – 5.00 (m, 1H), 4.03 (t, J = 6.7 Hz, 2H), 2.03 (s, 3H), 1.79 – 1.54 (m, 6H), 1.47 – 1.27 (m, 6H), 
0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 166.5, 132.8, 130.9, 129.6, 128.4, 76.2, 64.7, 33.7, 29.3, 
28.6, 27.2, 25.9, 25.4, 21.1, 9.8. 
FT-IR (film): 3548, 2936, 1715, 1602, 1453, 1365, 1271, 1110, 711 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C18H26NaO4: 329.1723, found: 329.1731. 
[α]23D = −8.5 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 
 
 
9-Hydroxynonan-3-yl benzoate (Figure 4, entry 40).  In the air, HBF4⋅Et2O (0.10 mL) was 
added to a solution of the acetate (61.2 mg, 0.20 mmol, 1.0 equiv) in MeOH (2 mL) at room 
temperature, and the resulting reaction mixture was stirred at room temperature for 3 h.  
Next, the reaction mixture was concentrated, and then the residue was purified by flash 
chromatography on silica gel (1:2 Et2O/hexanes).  Colorless oil.  The analytical data matched 
the literature report.3a 
(S,S)-L*: 50.4 mg, 95% yield, 90% ee; (R,R)-L*: 49.7 mg, 94% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ column (5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 9.3 min 
(minor), 10.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 8.12 – 7.97 (m, 2H), 7.63 – 7.49 (m, 1H), 7.49 – 7.36 (m, 2H), 
5.16 – 4.99 (m, 1H), 3.60 (t, J = 6.6 Hz, 2H), 1.77 – 1.59 (m, 5H), 1.58 – 1.47 (m, 2H), 1.44 – 1.27 
(m, 6H), 0.94 (t, J = 7.4 Hz, 3H). 
S–45 
13C NMR (101 MHz, CDCl3) δ 166.6, 132.8, 130.9, 129.6, 128.4, 76.2, 63.0, 33.7, 32.7, 29.4, 27.2, 
25.7, 25.4, 9.8. 
FT-IR (film): 3370, 2939, 2361, 1717, 1275, 1100, 713 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C16H24NaO3: 287.1618, found: 287.1623. 
[α]23D = −9.5 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 
 
 
1-Phenylundecan-3-yl acetate (Figure 4, entry 41).  The title compound was synthesized 
according to GP-8 from acetyl bromide, 3-phenylpropanal, and 1-octene.  The product was 
purified by column chromatography on silica gel (1:20 Et2O/hexanes).  Colorless oil.  The 
analytical data matched the literature report.4a 
(S,S)-L*: 130 mg, 56% yield, 90% ee; (R,R)-L*: 119 mg, 51% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (0.5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L*: 6.2 min 
(major), 7.0 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.24 (m, 2H), 7.23 – 7.12 (m, 3H), 5.02 – 4.86 (m, 1H), 
2.71 – 2.51 (m, 2H), 2.04 (s, 3H), 1.96 – 1.78 (m, 2H), 1.65 – 1.48 (m, 2H), 1.38 – 1.16 (m, 12H), 
0.88 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.1, 141.9, 128.5, 128.4, 126.0, 74.1, 36.0, 34.3, 32.0, 31.9, 29.7, 
29.6, 29.4, 25.4, 22.8, 21.4, 14.3. 
FT-IR (film): 2931, 1738, 1455, 1377, 1240, 1024, 740 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C19H30NaO2: 313.2138, found: 313.2133. 
[α]23D = −9.5 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 
 
 
Heptadecan-7-yl propionate (Figure 4, entry 42).  The title compound was synthesized 
according to GP-8 from propionyl bromide, heptanal, and 1-decene.  The product was 
purified by column chromatography on silica gel (1:20 Et2O/hexanes).  Colorless oil.  The 
analytical data matched the literature report.5 
(S,S)-L*: 131 mg, 53% yield, 92% ee; (R,R)-L*: 128 mg, 51% yield, 93% ee. 
HPLC analysis: The ee was determined after transforming the product to the 
corresponding phosphate (see below). 
1H NMR (400 MHz, CDCl3) 4.92 – 4.81 (m, 1H), 2.30 (q, J = 7.6 Hz, 2H), 1.56 – 1.44 (m, 4H), 
1.36 – 1.18 (m, 24H), 1.14 (t, J = 7.6 Hz, 3H), 0.93 – 0.81 (m, 6H). 
n-Hex
O
n-Oct
Et
O
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13C NMR (101 MHz, CDCl3) δ 174.5, 74.3, 34.3, 32.1, 31.9, 29.8, 29.72, 29.69, 29.5, 29.4, 28.1, 
25.5, 25.4, 22.8, 22.7, 14.3, 14.2, 9.5. 
FT-IR (film): 2926, 1738, 1463, 1379, 1275, 1192, 1082, 723 cm-1. 
[α]22D = +2.1 (c 1.0, CHCl3); 92% ee, from (S,S)-L*. 
 
 
 
Heptadecan-7-yl diphenyl phosphate.  The title compound was synthesized according to 
GP-5.  The product was purified by column chromatography on silica gel (1:5 
EtOAc/hexanes).  Colorless oil. 
(S,S)-L*: 93.7 mg, 96% yield, 92% ee; (R,R)-L*: 91.2 mg, 93% yield, 93% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALCEL OD column (4% CH3CN in 
supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L*: 14.7 min 
(major), 15.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 4H), 7.26 – 7.20 (m, 4H), 7.20 – 7.13 (m, 2H), 
4.74 – 4.54 (m, 1H), 1.71 – 1.52 (m, 4H), 1.36 – 1.14 (m, 24H), 0.93 – 0.81 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 150.9 (d, J = 7.1 Hz), 129.8, 125.2 (d, J = 1.0 Hz), 120.2 (d, J = 5.1 
Hz), 82.5 (d, J = 7.1 Hz), 35.1 (d, J = 5.1 Hz), 32.0, 31.8, 29.71, 29.65, 29.6, 29.5, 29.4, 29.2, 24.9, 
24.8, 22.8, 22.7, 14.24, 14.17. 
31P NMR (162 MHz, CDCl3) δ –12.4.  
FT-IR (film): 3485, 2916, 1592, 1495, 1296, 1198, 1020, 753 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C29H49NO4P: 506.3394, found: 506.3399. 
[α]22D = +3.6 (c 1.0, CHCl3); 92% ee, from (S,S)-L*. 
 
 
 
Heptadecan-7-yl propionate (Figure 4, entry 42).  The title compound was synthesized 
according to GP-8 from propionyl bromide, undecanal, and 1-hexene.  The product was 
purified by column chromatography on silica gel (1:20 Et2O/hexanes).  Colorless oil. 
(S,S)-L*: 135 mg, 54% yield, 93% ee; (R,R)-L*: 138 mg, 55% yield, 93% ee. 
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VIII.  Assignment of Absolute Configuration 
 
The configurations of the coupling products were assigned by comparison with published 
optical-rotation data. 
 
 
(R)-Hexan-3-yl benzoate (Figure 3, entry 18).  The absolute configuration of this 
compound has been reported.7  The material obtained with (S,S)-L* has the (R) configuration, 
by comparison with the sign of the published optical rotation. 
Optical rotation: [α]23D = −4.8 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
 Lit.: [α]26D = −2.1 (c 1.1, CHCl3); 99% ee, (R) configuration. 
 
 
 
(R)-Nonan-3-yl benzoate (Figure 3, entry 20).  The absolute configuration of this 
compound has been reported.6  The material obtained with (S,S)-L* has the (R) configuration, 
by comparison with the sign of the published optical rotation. 
Optical rotation: [α]23D = −8.9 (c 1.0, CHCl3); 89% ee, from (S,S)-L*. 
 Lit.: [α]26D = −30 (c 0.975, CHCl3); 99% ee, (R) configuration. 
 
 
 
(R)-9-Hydroxynonan-3-yl benzoate (Figure 4, entry 40).  The absolute configuration of 
this compound has been reported.3a  The material obtained with (S,S)-L* has the (R) 
configuration, by comparison with the published optical rotation. 
Optical rotation: [α]23D = −9.5 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 Lit.: [α]20D = −8.6 (c 1.3, CHCl3); 99% ee, (R) configuration. 
 
 
  
S–48 
 
(S)-1-Phenylundecan-3-yl acetate (Figure 4, entry 41).  The absolute configuration of this 
compound has been reported.4a  The material obtained with (S,S)-L* has the (S) configuration, 
by comparison with the sign of the published optical rotation. 
Optical rotation: [α]23D = −9.5 (c 1.0, CHCl3); 90% ee, from (S,S)-L*. 
 Lit.: [α]22D = +4.9 (c 1.0, CHCl3); ee not provided; (R) configuration. 
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4‐Cyclohexylbutan‐2‐yl benzoate (Fig. 3, entry 1) 
HPLC Analysis: CHIRALPAK IC column (0.5% i‐PrOH in hexane, 0.5 mL/min). 
Compound 1: 92% ee from (S,S)‐L* 
 
 
 
Compound 1: 93% ee from (R,R)‐L* 
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1‐Cyclohexylpentan‐3‐yl benzoate (Fig. 3, entry 2) 
HPLC Analysis: CHIRALPAK IC column (0.5% i‐PrOH in hexane, 0.5 mL/min). 
Compound 2: 92% ee from (S,S)‐L* 
 
 
 
 
Compound 2: 92% ee from (R,R)‐L* 
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1‐Cyclohexylpentan‐3‐yl benzoate (Fig. 3, entry 3) 
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HPLC Analysis: CHIRALPAK AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
94% ee from (S,S)‐L* 
 
 
 
 
92% ee from (R,R)‐L* 
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1‐Cyclohexyl‐5‐methylhexan‐3‐yl benzoate (Fig. 3, entry 4) 
Determination of the ee: 
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Cy
NaOH, MeOH DMAP, (PhO)2POCl
50 °C r.t.
O
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P
OPh
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Cy
OPh
 
HPLC Analysis: CHIRALPAK AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
95% ee from (S,S)‐L* 
 
 
 
 
95% ee from (R,R)‐L* 
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1‐Cyclohexyl‐5,5‐dimethylhexan‐3‐yl benzoate (Fig. 3, entry 5) 
Determination of the ee: 
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HPLC Analysis: CHIRALPAK AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
94% ee from (S,S)‐L* 
 
 
 
 
94% ee from (R,R)‐L* 
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1‐Cyclobutyl‐3‐cyclohexylpropyl benzoate (Fig. 3, entry 6) 
Determination of the ee: 
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50 °C r.t.
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HPLC Analysis: CHIRALPAK IC column (10% i‐PrOH in hexane, 1.0 mL/min). 
98% ee from (S,S)‐L* 
 
 
 
 
98% ee from (R,R)‐L* 
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1,3‐Dicyclohexylpropyl benzoate (Fig. 3, entry 7) 
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HPLC Analysis: CHIRALPAK AS column (5% i‐PrOH in hexane, 1.0 mL/min). 
96% ee from (S,S)‐L* 
 
 
 
 
95% ee from (R,R)‐L* 
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1‐Cyclohexyl‐4‐methylpentan‐3‐yl benzoate (Fig. 3, entry 8) 
HPLC Analysis: CHIRALPAK IC column (0.5% i‐PrOH in hexane, 0.5 mL/min). 
Compound 8: 94% ee from (S,S)‐L* 
 
 
 
 
Compound 8: 95% ee from (R,R)‐L* 
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1‐Cyclohexyl‐5‐phenylpentan‐3‐yl benzoate (Fig. 3, entry 9) 
HPLC Analysis: CHIRALCEL OD column (1% i‐PrOH in hexane, 1.0 mL/min). 
Compound 9: 92% ee from (S,S)‐L* 
 
 
 
 
Compound 9: 92% ee from (R,R)‐L* 
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3‐Cyclohexyl‐1‐(tetrahydro‐2H‐pyran‐4‐yl)propyl benzoate (Fig. 3, entry 10) 
HPLC Analysis: CHIRALPAK IC column (3% i‐PrOH in hexane, 1.0 mL/min). 
Compound 10: 97% ee from (S,S)‐L* 
 
 
 
 
Compound 10: 96% ee from (R,R)‐L* 
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8‐Chloro‐1‐cyclohexyloctan‐3‐yl benzoate (Fig. 3, entry 11) 
HPLC Analysis: CHIRALPAK AD column (1% i‐PrOH in hexane, 1.0 mL/min). 
Compound 11: 92% ee from (S,S)‐L* 
 
 
 
 
Compound 11: 92% ee from (R,R)‐L* 
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8‐Bromo‐1‐cyclohexyloctan‐3‐yl benzoate (Fig. 3, entry 12) 
HPLC Analysis: CHIRALPAK IC column (0.5% i‐PrOH in hexane, 0.5 mL/min). 
Compound 12: 94% ee from (S,S)‐L* 
 
 
 
 
Compound 12: 92% ee from (R,R)‐L* 
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(5S)‐1‐Cyclohexyl‐5,9‐dimethyldecan‐3‐ol (Fig. 3, entries 13 and 14) 
Determination of the ee: 
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HPLC Analysis: AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
4:96 d.r. ee from (S,S)‐L* 
 
 
 
 
96:4 d.r. from (R,R)‐L* 
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12‐Phenoxydodecan‐6‐yl acetate (Fig. 3, entry 15) 
HPLC Analysis: CHIRALCEL OD column (2% i‐PrOH in hexane, 1.0 mL/min). 
Compound 15: 93% ee from (S,S)‐L* 
 
 
 
 
Compound 15: 92% ee from (R,R)‐L* 
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12‐Phenoxydodecan‐6‐yl isobutyrate (Fig. 3, entry 16) 
HPLC Analysis: CHIRALPAK AD column (0.5% i‐PrOH in hexane, 1.0 mL/min). 
Compound 16: 94% ee from (S,S)‐L* 
 
 
 
 
Compound 16: 95% ee from (R,R)‐L* 
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9‐Phenoxynonan‐3‐yl pivalate (Fig. 3, entry 17) 
HPLC Analysis: CHIRALPAK AD column (0.5% i‐PrOH in hexane, 0.5 mL/min). 
Compound 17: 91% ee from (S,S)‐L* 
 
 
 
 
Compound 17: 92% ee from (R,R)‐L* 
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Hexan‐3‐yl benzoate (Fig. 3, entry 18) 
Determination of the ee: 
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HPLC Analysis: CHIRALPAK AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
89% ee from (S,S)‐L* 
 
 
 
 
87% ee from (R,R)‐L* 
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Heptan‐3‐yl benzoate (Fig. 3, entry 19) 
Determination of the ee: 
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HPLC Analysis: CHIRALPAK AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
91% ee from (S,S)‐L* 
 
 
 
 
90% ee from (R,R)‐L* 
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Nonan‐3‐yl benzoate (Fig. 3, entry 20) 
Determination of the ee: 
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HPLC Analysis: AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
89% ee from (S,S)‐L* 
 
 
 
 
89% ee from (R,R)‐L* 
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7‐Methyloctan‐3‐yl benzoate (Fig. 3, entry 21) 
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HPLC Analysis: CHIRALPAK AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
90% ee from (S,S)‐L* 
 
 
 
 
91% ee from (R,R)‐L* 
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6‐Cyclopentylhexan‐3‐yl benzoate (Fig. 3, entry 22) 
HPLC Analysis: CHIRALPAK IC column (0.5% i‐PrOH in hexane, 0.5 mL/min). 
Compound 22: 88% ee from (S,S)‐L* 
 
 
 
 
Compound 22: 89% ee from (R,R)‐L* 
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6‐Cyclohexylhexan‐3‐yl benzoate (Fig. 3, entry 23) 
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HPLC Analysis: CHIRALPAK AD column (10% i‐PrOH in hexane, 1.0 mL/min). 
90% ee from (S,S)‐L* 
 
 
 
 
90% ee from (R,R)‐L* 
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7,7‐Dimethyloctan‐3‐yl benzoate (Fig. 3, entry 24) 
HPLC Analysis: CHIRALPAK AD column (0.5% i‐PrOH in hexane, 0.5 mL/min). 
Compound 24: 88% ee from (S,S)‐L* 
 
 
 
 
Compound 24: 89% ee from (R,R)‐L* 
 
 
S–224 
O
Et
Ph
O
MeO2C  
9‐Methoxy‐9‐oxononan‐3‐yl benzoate (Fig. 3, entry 25) 
HPLC Analysis: CHIRALPAK AD column (1% i‐PrOH in hexane, 1.0 mL/min). 
Compound 25: 86% ee from (S,S)‐L* 
 
 
 
 
Compound 25: 88% ee from (R,R)‐L* 
 
 
S–225 
O
Et
Ph
O
PhO  
7‐Phenoxyheptan‐3‐yl benzoate (Fig. 3, entry 26) 
HPLC Analysis: CHIRALPAK AD column (1% i‐PrOH in hexane, 0.5 mL/min). 
Compound 26: 89% ee from (S,S)‐L* 
 
 
 
 
Compound 26: 90% ee from (R,R)‐L* 
 
 
S–226 
O
Et
Ph
O
Br  
9‐Bromononan‐3‐yl benzoate (Fig. 3, entry 27) 
HPLC Analysis: CHIRALPAK AD column (0.5% i‐PrOH in hexane, 1.0 mL/min). 
Compound 27: 92% ee from (S,S)‐L* 
 
 
 
 
Compound 27: 90% ee from (R,R)‐L* 
 
 
S–227 
O
Et
Ph
O
Cl  
9‐Chlorononan‐3‐yl benzoate (Fig. 3, entry 28) 
HPLC Analysis: CHIRALPAK AD column (1% i‐PrOH in hexane, 1.0 mL/min). 
Compound 28: 88% ee from (S,S)‐L* 
 
 
 
 
Compound 28: 87% ee from (R,R)‐L* 
 
 
S–228 
O
Et
Ph
O
O
O  
8‐(1,3‐Dioxan‐2‐yl)octan‐3‐yl benzoate (Fig. 3, entry 29) 
HPLC Analysis: CHIRALPAK AD column (1% i‐PrOH in hexane, 1.0 mL/min). 
Compound 29: 89% ee from (S,S)‐L* 
 
 
 
 
Compound 29: 88% ee from (R,R)‐L* 
 
 
S–229 
Et
O Ph
O
H
Me
H H
O
O
O  
8‐(((8R,9S,13S,14S)‐13‐methyl‐6,7,8,9,11,12,13,14,15,16‐
decahydrospiro[cyclopenta[a]phenanthrene‐17,2ʹ‐[1,3]dioxolan]‐3‐yl)oxy)octan‐3‐yl benzoate 
(Fig. 3, entries 30 and 31) 
HPLC Analysis: CHIRALPAK IC column (5% i‐PrOH in hexane, 1.0 mL/min). 
Compound 30: 95:5 d.r. from (S,S)‐L* 
 
 
 
 
Compound 31: 7:93 d.r. from (R,R)‐L* 
 
 
S–230 
O
Et
Ph
O
EtO2CO  
9‐((Ethoxycarbonyl)oxy)nonan‐3‐yl benzoate (Fig. 3, entry 32) 
HPLC Analysis: CHIRALPAK AD column (1% i‐PrOH in hexane, 1.0 mL/min). 
Compound 32: 91% ee from (S,S)‐L* 
 
 
 
 
Compound 32: 91% ee from (R,R)‐L* 
 
 
S–231 
O
Et
Ph
O
Bpin
 
8‐(4,4,5,5‐Tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)octan‐3‐yl benzoate (Fig. 3, entry 33) 
HPLC Analysis: CHIRALPAK IC column (5% i‐PrOH in hexane, 1.0 mL/min). 
Compound 33: 88% ee from (S,S)‐L* 
 
 
 
 
Compound 33: 89% ee from (R,R)‐L* 
 
 
S–232 
O
Et
Ph
O
PhthN
 
8‐(1,3‐Dioxoisoindolin‐2‐yl)octan‐3‐yl benzoate (Fig. 3, entry 34) 
HPLC Analysis: CHIRALPAK IC column (10% i‐PrOH in hexane, 1.0 mL/min). 
Compound 34: 89% ee from (S,S)‐L* 
 
 
 
 
Compound 34: 89% ee from (R,R)‐L* 
 
 
S–233 
O
Me
O
Cl
Bpin
 
1‐Chloro‐10‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)decan‐5‐yl (1r,4r)‐4‐
methylcyclohexane‐1‐carboxylate (Fig. 4, entry 38) 
Determination of the ee: 
O
Me
O
Cl
Bpin
NaBO3 • 4H2O
THF/H2O
BzCl, pyridine
DCM
O
Me
O
Cl
BzO
 
 
HPLC Analysis: CHIRALCEL OD column (3% i‐PrOH in hexane, 1.0 mL/min). 
92% ee from (S,S)‐L* 
 
 
 
 
92% ee from (R,R)‐L* 
 
 
S–234 
O Ph
O
Me
AcO  
9‐Acetoxynonan‐3‐yl benzoate (Fig. 4, entry 39) 
HPLC Analysis: CHIRALPAK AD column (2% i‐PrOH in hexane, 1.0 mL/min). 
Compound 39: 90% ee from (S,S)‐L* 
 
 
 
 
Compound 39: 89% ee from (R,R)‐L* 
 
 
S–235 
O Ph
O
Me
HO  
9‐Hydroxynonan‐3‐yl benzoate (Fig. 4, entry 40) 
HPLC Analysis: CHIRALCEL OJ column (5% i‐PrOH in hexane, 1.0 mL/min). 
Compound 40: 90% ee from (S,S)‐L* 
 
 
 
 
Compound 40: 89% ee from (R,R)‐L* 
 
 
S–236 
O Me
O
Phn-Hex  
1‐Phenylundecan‐3‐yl acetate (Fig. 4, entry 41) 
HPLC Analysis: CHIRALPAK AD column (0.5% i‐PrOH in hexane, 1.0 mL/min). 
Compound 41: 90% ee from (S,S)‐L* 
 
 
 
 
Compound 41: 90% ee from (R,R)‐L* 
 
 
S–237 
n-Dec
O
n-Bu
Et
O
 
Heptadecan‐7‐yl propionate (Fig. 4, entry 42) 
Determination of the ee: 
O
n-Dec
Et
O
n-Bu
NaOH, MeOH DMAP, (PhO)2POCl
50 °C r.t.
O
n-Dec
P
OPh
O
n-Bu
OPh
 
 
SFC Analysis: CHIRALCEL OD column (4% CH3CN in supercritical CO2, 2.5 mL/min). 
Compound 42: 92% ee from (S,S)‐L* 
 
 
 
 
Compound 42: 93% ee from (R,R)‐L* 
 
 
 
 
